

Review

Reference Values for Skeletal Muscle Mass – Current Concepts and Methodological Considerations

Carina O. Walowski¹, Wiebke Braun¹, Michael J. Maisch², Björn Jensen², Sven Peine³, Kristina Norman^{4,5}, Manfred J. Müller¹ and Anja Bosy-Westphal^{1,*}

¹ Institute for Human Nutrition and Food Science, Christian-Albrechts-University Kiel, 24105 Kiel, Germany; cwalowski@nutrition.uni-kiel.de (C.O.W.); wbraun@nutrition.uni-kiel.de (W.B.); mmueller@nutrfoodsc.uni-kiel.de (M.J.M.)

² seca gmbh & co. kg., Hammer Steindamm 3-25, 22089 Hamburg, Germany; michael.maisch@seca.com (M.J.M.); bjoern.jensen@seca.com (B.J.)

³ Institute for Transfusion Medicine, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany; s.peine@uke.de

⁴ Department of Nutrition and Gerontology, German Institute of Human Nutrition, Potsdam-Rehbruecke, 14558 Berlin, Germany; kristina.norman@dife.de

⁵ Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 13347 Berlin, Germany

* Correspondence: abosyw@nutrition.uni-kiel.de; Tel.: +49-(0)431-880-5674

Received: 17 February 2020; Accepted: 9 March 2020; Published: 12 March 2020



Abstract: Assessment of a low skeletal muscle mass (SM) is important for diagnosis of ageing and disease-associated sarcopenia and is hindered by heterogeneous methods and terminologies that lead to differences in diagnostic criteria among studies and even among consensus definitions. The aim of this review was to analyze and summarize previously published cut-offs for SM applied in clinical and research settings and to facilitate comparison of results between studies. Multiple published reference values for discrepant parameters of SM were identified from 64 studies and the underlying methodological assumptions and limitations are compared including different concepts for normalization of SM for body size and fat mass (FM). Single computed tomography or magnetic resonance imaging images and appendicular lean soft tissue by dual X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) are taken as a valid substitute of total SM because they show a high correlation with results from whole body imaging in cross-sectional and longitudinal analyses. However, the random error of these methods limits the applicability of these substitutes in the assessment of individual cases and together with the systematic error limits the accurate detection of changes in SM. Adverse effects of obesity on muscle quality and function may lead to an underestimation of sarcopenia in obesity and may justify normalization of SM for FM. In conclusion, results for SM can only be compared with reference values using the same method, BIA- or DXA-device and an appropriate reference population. Limitations of proxies for total SM as well as normalization of SM for FM are important content-related issues that need to be considered in longitudinal studies, populations with obesity or older subjects.

Keywords: sarcopenia; sarcopenic obesity; skeletal muscle mass; skeletal muscle area; skeletal muscle mass index; appendicular skeletal muscle mass index; fat-free mass index

1. Introduction

Beyond the well-established role of ageing associated loss in skeletal muscle mass (SM) (primary sarcopenia) as a risk factor of frailty, morbidity and mortality in older people, a low SM is observed as a result of diseases like malignant cancer, chronic obstructive pulmonary disease, heart failure and

renal failure (secondary sarcopenia [1]) and is also an emerging prognostic marker in a number of diseases [2–12]. The etiology for sarcopenia as a risk factor might be partly explained by the correlation between SM and cardiac, respiratory or immune function but remains to be investigated further in order to understand the preventative and therapeutic potential of SM. Muscle not only functions as the major tissue for insulin-stimulated glucose uptake, amino acid storage and thermoregulation, but is also secreting a large number of myokines that regulate metabolism in muscle itself as well as in other tissues and organs including adipose tissue, the liver and the brain [13,14]. The recent popularity of SM outpaced the interest in fat mass (FM) that only has a limited and inconsistent impact on morbidity and mortality [15,16]. The assessment of SM by segmentation of continuous whole body magnetic resonance imaging (MRI) is considered as the gold standard [17]. However, this method is too cumbersome and expensive for clinical practice and is even rarely used in studies with larger sample sizes [17,18]. Instead, single slices at different reference sites measured by MRI or obtained from routine computed tomography (CT) examinations are taken as a proxy for the total tissue volume (e.g., L3 muscle cross-sectional area [17,19]). Most commonly, dual X-ray absorptiometry (DXA) is used to assess appendicular lean soft tissue (ASM, the sum of lean soft tissue from both arms and legs) or fat-free mass (FFM, total lean soft tissue plus bone mineral mass or body weight minus FM) as a proxy for SM. More simple and even non-invasive, the output of bioelectrical impedance analysis (BIA) depends on the reference method used to generate the BIA algorithm and can be FFM [20], ASM, e.g., [21–23] or even SM, e.g., [24–27].

To facilitate comparison between studies and to evaluate individual results for SM in patients, it is important to understand the differences between parameters and cut-offs for SM. These differences are not only method inherent but also depend on characteristics of the study population (e.g., ethnicity, age and disease). Device-specific characteristics by different manufacturers determine the validity and precision of parameters for SM. In addition, the available reference values differ with respect to parametric normalization (linear regression or indexing) to account for body size. Further complexity to the definition of a normal SM is derived from the concept of sarcopenic obesity [28]. Since high levels of FM may adversely affect the quality and function of SM [29,30], a normal SM may also depend on the amount of FM.

Different professional associations have published definitions of sarcopenia based on an estimate of SM and impaired muscle strength and/or physical performance [31–37], but no consensus definition has yet been reached. The aim of this review is not to provide an optimal diagnosis of sarcopenia but to compare current definitions of a low SM considering the impact of the underlying methodological assumptions, limitations and normalization of SM parameters for height, weight, body mass index (BMI) or FM.

2. Methods

In order to identify reference values for SM, seven consensus reports were reviewed [31–37]. Further studies were identified through reference lists and a search for relevant articles based on the keywords “sarcopenia”, “low muscle mass”, “cut-off sarcopenia”, “reference value sarcopenia”, “sarcopenic obesity”. Only parameters of SM normalized for height, weight, BMI or FM were considered. To be included in this article, studies were required to contain the following information: method of SM assessment (device), cut-off points for SM and description of the reference population including geographical location, sample size, distribution between sexes and age (range and/or standard deviation (SD) \pm mean). Only English language articles were considered. Therefore, 64 studies were identified that met the inclusion criteria. Main reasons for the exclusion of articles were duplicate analyses conducted on the same reference population (only the first published paper was included), a missing normalization of reference values, a sample size <200 subjects (sample size <200 subjects will not be representative for both sexes, all ages and BMI-groups), the use of anthropometric measures to determine a low SM and the adoption of previously published cut-offs regarding SM and obesity.

Study Characteristics

Studies that met the inclusion criteria were published between 1998 and 2019 and were performed in 21 countries. The sample size of the individual studies ranged from 200 to 38,099 subjects with an age range between 18 and >90 years. In 36 studies, the authors clearly indicated that the reference population included healthy individuals.

3. Results

Published cut-off points for a low SM normalized by height are presented in Tables 1–3 stratified by DXA, BIA and CT. In the majority of studies (14 of 32), SM was measured by DXA using lean soft tissue from the arms and legs normalized by height² given as appendicular skeletal muscle mass index (ASMI) [22,38–50]. One study [40] used DXA-derived ASM to predict whole body SM measured by MRI using the equation by Kim et al. [51] that was validated in an ethnically diverse sample of healthy men and women. The range of published cut-off values for ASMI by DXA (without considering different classes of sarcopenia) was 5.86–7.40 kg/m² in men and 4.42–5.67 kg/m² in women.

With ten studies, the second most commonly used method underlying published SM reference values was BIA [21–26,52–55]. To measure SM by BIA, five studies have used the BIA-equation by Janssen et al. [56] to predict SM [24–26,53,55]. This BIA-equation was developed and cross-validated against whole body MRI in a sample of 269 Caucasian men and women aged 18 to 86 years with a BMI of 16–48 kg/m² using a model 101B BIA analyzer (RJL Systems, Detroit, MI, USA) [56]. The authors reported that the BIA-equation is applicable for Caucasian, African-American, and Hispanic populations but has not been validated for the estimation of SM in Asian populations. One study calculated SM by multiplying BIA-derived FFM with a constant factor (0.566) derived from comparison with SM estimates by 24 h creatinine excretion in healthy subjects [52]. The range of cut-offs for ASMI by BIA was 6.75–7.40 kg/m² in men and 5.07–5.80 kg/m² in women, whereas cut-offs for skeletal muscle mass index (SMI) by BIA validated against MRI ranged between 7.70 and 9.20 kg/m² in men and 5.67 and 7.40 kg/m² in women (without considering severity of sarcopenia).

Nine studies used standard diagnostic CT to determine SM cut-off points for single slices [57–65]. Skeletal muscle area (SMA) at the level of the third lumbar vertebra (L3 SMA; L3 SMI = L3 SMA/height², cm²/m²) was used in three studies on patients with cancer [62,64,65]. Cut-off points ranged between 36.00 and 43.20 cm²/m² in men and 29.00 and 34.90 cm²/m² in women. Six studies determined sex-specific cut-offs for SM by CT in healthy populations, thereof five in organ donors [57–61,63]. L3 SMI was used in four studies on healthy subjects [57–60] and three studies with a healthy reference group used CT imaging at the L3 level to measure the psoas muscle mass area (L3 PMA; L3 psoas muscle index (PMI) = L3 PMA/height², cm²/m²) [57,61,63]. In healthy populations, cut-off values for L3 SMI ranged between 36.54 and 45.40 cm²/m² in men and 30.21 and 36.05 cm²/m² in women, whereas thresholds for L3 PMI were 2.63–6.36 cm²/m² for men and 1.48–4.00 cm²/m² for women.

Table 1. Cut-off values and diagnostic criteria of a low muscle mass using dual X-ray absorptiometry (DXA).

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | | |
|--------------------------|--|---|--|---|--------------|--------------|
| Alkahtani (2017) | Lunar iDXA General Electric machine, Healthcare | ASMI Class I and Class II sarcopenia men: 7.74 kg/m ² and 6.51 kg/m ² | n = 232 Saudi Arabians | | | |
| | | | n | men 232 | women 0 | |
| | | | Age (y) | 27.1 ± 4.2 | | |
| | | | BMI (kg/m ²) | 28.1 ± 5.5 | | |
| | | | → Class I sarcopenia: 1 SD below the means for young, healthy adults | | | |
| | | | → Class II sarcopenia: 2 SDs below the means for young, healthy adults | | | |
| Imboden et al. (2017) | GE Lunar Prodigy or iDXA | (a) ASMI men: 6.35 kg/m ² women: 4.92 kg/m ² | (a) n = 1246 US population | | | |
| | | | n | men 488 | women 758 | |
| | | | Age (y) | 20 to 39 | 20 to 39 | |
| | | | BMI (kg/m ²) | NA | NA | |
| | | | | → 2 SDs below the sex-specific means of young adults | | |
| | | | | (b) n = 351 US population | | |
| | (b) ASMI men: 7.40 kg/m ² women: 5.60 kg/m ² | n | men 168 | women 183 | | |
| Age (year) | | 70 to 79 | 70 to 79 | | | |
| BMI (kg/m ²) | | NA | NA | | | |
| | | → sex-specific lowest 20% of study group | | | | |
| Kruger et al. (2015) | | Hologic Discovery-W, software version 12.7 for Cape Town QDR-4500A, software version 12.5:7 for Soweto | (a) ASMI women: 4.93 kg/m ² | (a) n = 238 Black South Africans (Cape Town) | | |
| | | | | n | men 0 | women 238 |
| | Age (year) | | | | 25.8 ± 5.9 | |
| | BMI (kg/m ²) | | | | 29.8 ± 8.0 | |
| | | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| | | | | (b) n = 371 Black South Africans (Soweto) | | |
| | (b) ASMI women: 4.95 kg/m ² | n | men 0 | women 371 | | |
| Age (year) | | | 35.1 ± 3.2 | | | |
| BMI (kg/m ²) | | | 28.8 ± 6.2 | | | |
| | | → 2 SDs below the sex-specific means of young, healthy adults | | | | |

Table 1. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|---------------------------------------|---|--|---|---|---------------|
| Alemán-Mateo & Ruiz Valenzuela (2014) | DPX-MD+, GE Lunar | ASMI | <i>n</i> = 216 | Mexicans | |
| | | men: 5.86 kg/m ² women: 4.72 kg/m ² | <i>n</i> | men 136 | women 80 |
| | | SMI | Age (year) | 27.3 ± 5.0 | 28.2 ± 5.6 |
| | | men: 6.63 kg/m ² women: 5.22 kg/m ² | BMI (kg/m ²) | 25.7 ± 3.6 | 23.2 ± 3.1 |
| | | SM was predicted using Kim's equation (Kim et al., 2002) | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Gould et al. (2014) | DPX-L scanner, software version 1.31; Lunar or Prodigy Pro, Lunar | ASMI | <i>n</i> = 682 | study performed in southeastern Australia | |
| | | men: 6.94 kg/m ² women: 5.30 kg/m ² | <i>n</i> | men 374 | women 308 |
| | | | Age (year) | 20 to 39 | 20 to 39 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| Marwaha et al. (2014) | Prodigy Oracle, GE Lunar Corp. | (a) ASMI | (a) <i>n</i> = 469 | Indians | |
| | | women: 4.42 kg/m ² | <i>n</i> | men 0 | women 469 |
| | | | Age (year) | 20 to 39 | |
| | | | BMI (kg/m ²) | NA | |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| | | (b) ASMI | (b) <i>n</i> = 1045 | Indians | |
| | | women: 5.11 kg/m ² | <i>n</i> | men 0 | women 1045 |
| | | | Age (year) | 44.0 ± 17.1 | |
| | | | BMI (kg/m ²) | 25.0 ± 5.2 | |
| | | | → sex-specific lowest 20% of study group | | |
| Yu et al. (2014) | Hologic Delphi W4500 densitometer, auto whole body version 12.4 | ASMI | <i>n</i> = 4000 | Chinese (Hong Kong) | |
| | | men: 6.52 kg/m ² women: 5.44 kg/m ² | <i>n</i> | men 2000 | women 2000 |
| | | | Age (year) | 72.5 ± 5.2 | 72.5 ± 5.2 |
| | | | BMI (kg/m ²) | 23.7 ± 3.3 | 23.7 ± 3.3 |
| | | | → lowest quintile | | |

Table 1. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|------------------------|--|---|--|-------------------------------------|------------|
| Kim et al. (2012) | Hologic Discovery-W | ASMI Class I and Class II sarcopenia men: 7.50 kg/m ² and 6.58 kg/m ² women: 5.38 kg/m ² and 4.59 kg/m ² | <i>n</i> = 2513 | Koreans | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 1245 | 1268 |
| | | | BMI (kg/m ²) | 31.0 ± 5.5 | 30.8 ± 5.6 |
| | | | | 24.0 ± 3.4 | 22.1 ± 3.5 |
| | | | → Class I sarcopenia: 1-2 SDs below the sex-specific means for young, healthy adults | | |
| | | | → Class II sarcopenia: 2 SDs below the sex-specific means for young, healthy adults | | |
| Oliveira et al. (2011) | DPX-L, Lunar Radiation Corporation | ASMI women: 5.0 kg/m ² | <i>n</i> = 349 | Brazilians | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 0 | 349 |
| | | | BMI (kg/m ²) | 29.0 ± 7.5 | 23.5 ± 4.5 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Sanada et al. (2010) | Hologic QDR-4500A scanner, software version 11.2:3 | ASMI Class I and Class II sarcopenia men: 7.77 kg/m ² and 6.87 kg/m ² women: 6.12 kg/m ² and 5.46 kg/m ² | <i>n</i> = 529 | Japanese | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 266 | 263 |
| | | | BMI (kg/m ²) | 28.2 ± 7.4 | 28.0 ± 7.0 |
| | | | | 23.0 ± 3.0 | 20.8 ± 2.6 |
| | | | → Class I sarcopenia: 1 SD below the sex-specific means for young, healthy adults | | |
| | | | → Class II sarcopenia: 2 SDs below the sex-specific means for young, healthy adults | | |
| Szulc et al. (2004) | Hologic 1000W | ASMI men: 6.32 kg/m ² | <i>n</i> = 845 | study performed in France | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 845 | 0 |
| | | | BMI (kg/m ²) | 64.0 ± 8.0 | |
| | | | | 28.0 ± 3.7 | |
| | | | → lowest quartile | | |
| Newman et al. (2003) | QDR 4500A, Hologic, Inc. | ASMI men: 7.23 kg/m ² women: 5.67 kg/m ² Values recommended by the International Working Group on Sarcopenia (Fielding et al., 2011) | <i>n</i> = 2984 | study performed in USA (41% Blacks) | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 1435 | 1549 |
| | | | BMI (kg/m ²) | 73.6 ± 2.9 | 73.6 ± 2.9 |
| | | | | 27.4 ± 4.8 | 27.4 ± 4.8 |
| | | | → sex-specific lowest 20% of study group | | |

Table 1. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|---------------------------|--|--|--|------------|--------------|
| Tankó et al. (2002) | QDR4500A scanner, Hologic, software version V8.10a:3 and DPX scanner, Lunar Radiation, software versions 3.1 and 3.2 | (a) ASMI women: 6.10 kg/m ² (b) ASMI women: 5.40 kg/m ² | <i>n</i> = 216 women | | |
| | | | men | Danes | |
| | | | <i>n</i> | 0 | women 216 |
| | | | Age (year) | | 30.4 ± 5.3 |
| | | | BMI (kg/m ²) | | NA |
| | | | → (a) 1-2 SDs below the sex-specific means for young, healthy, premenopausal women | | |
| | | | → (b) 2 SDs below the sex-specific means for young, healthy, premenopausal women | | |
| Baumgartner et al. (1998) | Lunar DPX | ASMI men: 7.26 kg/m ² women: 5.45 kg/m ² | <i>n</i> = 229 | | |
| | | | US population (non-Hispanic white men and women) | | |
| | | | men | women | |
| | | | <i>n</i> | 107 | 122 |
| | | | Age (year) | 28.7 ± 5.1 | 29.7 ± 5.9 |
| | | | BMI (kg/m ²) | 24.6 ± 3.8 | 24.1 ± 5.4 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |

ASMI, appendicular skeletal muscle mass index; BMI, body mass index; DXA, dual X-ray absorptiometry; NA, not available; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index.

Table 2. Cut-off values and diagnostic criteria of a low muscle mass using bioelectrical impedance analysis (BIA).

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|------------------------------------|---|--|--|------------|------------|
| Krzymińska-Siemaszko et al. (2019) | InBody 170 analyzer, Biospace Co. | ASMI men: 7.35 kg/m ² (20–30 y), 7.38 kg/m ² (18–40 y, 18–39 y, 20–35 y), 7.40 kg/m ² (20–39 y, 20–40 y) women: 5.51 kg/m ² (20–30 y), 5.56 kg/m ² (18–40 y), 5.53 kg/m ² (18–39 y), 5.59 kg/m ² (20–39 y), 5.60 kg/m ² (20–40 y), 5.58 kg/m ² (20–35 y) Authors recommended the highest cut-off points, i.e., 5.60 kg/m ² in women and 7.40 kg/m ² in men | <i>n</i> = 1512 | | |
| | | | study performed in Poland (Caucasians) | | |
| | | | men | women | |
| | | | <i>n</i> | 635 | 877 |
| | | | Age (year) | 24.2 ± 5.3 | 28.4 ± 6.8 |
| | BMI (kg/m ²) | NA | NA | | |
| | | total <i>n</i> for men and women depends on age range | | | |
| | | → 2 SDs below the sex-specific means of young, healthy adults | | | |
| Alkahtani (2017) | Tanita MC-980MA, Tanita Corporation Inbody 770, Inbody Co. | ASMI Class I and Class II sarcopenia men: 8.68 kg/m ² and 7.45 kg/m ² ASMI Class I and Class II sarcopenia men: 7.29 kg/m ² and 6.42 kg/m ² | <i>n</i> = 232 | | |
| | | | Saudi Arabians | | |
| | | | men | women | |
| | | | <i>n</i> | 232 | 0 |
| | | | Age (year) | 27.1 ± 4.2 | |
| | | | BMI (kg/m ²) | 28.1 ± 5.5 | |
| | | | → Class I sarcopenia: 1 SD below the means for young, healthy adults | | |
| | | | → Class II sarcopenia: 2 SDs below the means for young, healthy adults | | |

Table 2. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|------------------------|---|---|---|---------------------------|------------|
| Bahat et al. (2016) | Tanita BC 532 model body analysis monitor | SMI men: 9.2 kg/m ² women: 7.4 kg/m ² SM (kg) = 0.566 × FFM | n = 301 | study performed in Turkey | |
| | | | n | men | women |
| | | | 187 | 114 | |
| | | | Age (year) | 26.8 ± 4.5 | 25.9 ± 4.7 |
| | | | BMI (kg/m ²) | 25.5 ± 3.6 | 22.4 ± 3.4 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Chang et al. (2013) | Tanita BC-418 | ASMI men: 6.76 kg/m ² women: 5.28 kg/m ² SMI men: 7.70 kg/m ² women: 5.67 kg/m ² SM by Janssen et al. (2000) equation | n = 998 | Taiwanese | |
| | | | n | men | women |
| | | | Age (year) | 23.1 ± 3.0 | 23.1 ± 2.7 |
| | | | BMI (kg/m ²) | 22.2 ± 3.1 | 20.2 ± 2.6 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Yamada et al. (2013) | Inbody 720, Biospace Co. | ASMI men: 6.75 kg/m ² women: 5.07 kg/m ² | n = 38,099 | Japanese | |
| | | | n | men | women |
| | | | Age (year) | 19,797 | 18,302 |
| | | | BMI (kg/m ²) | 18 to 40 | 18 to 40 |
| | | | NA | NA | |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| Masanés et al. (2012) | RJL Systems BIA 101 | SMI men: 8.25 kg/m ² women: 6.68 kg/m ² SM by Janssen et al. (2000) equation | n = 230 | study performed in Spain | |
| | | | n | men | women |
| | | | Age (year) | 110 | 120 |
| | | | BMI (kg/m ²) | 28.6 ± 5.0 | 28.2 ± 6.0 |
| | | | 24.6 ± 2.6 | 21.9 ± 2.2 | |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Tanimoto et al. (2012) | Tanita MC-190 | ASMI men: 7.0 kg/m ² women: 5.8 kg/m ² | n = 1719 | Japanese | |
| | | | n | men | women |
| | | | Age (year) | 838 | 881 |
| | | | BMI (kg/m ²) | 26.6 ± 6.7 | 28.5 ± 7.3 |
| | | | 22.4 ± 3.2 | 20.8 ± 2.9 | |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |

Table 2. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|-----------------------|---|--|---|---|------------|
| Chien et al. (2008) | Maltron BioScan 920 | SMI men: 8.87 kg/m ² women: 6.42 kg/m ² SM by Janssen et al. (2000) equation | <i>n</i> = 200 | Taiwanese | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 26.7 ± 5.7 | 27.6 ± 5.9 |
| | | | BMI (kg/m ²) | 23.2 ± 3.5 | 20.6 ± 2.5 |
| | | | → 2 SDs or more below the sex-specific means of young, healthy adults | | |
| Tichet et al. (2008) | Impedimed multifrequency analyser | SMI men: 8.60 kg/m ² women: 6.20 kg/m ² SM by Janssen et al. (2000) equation | <i>n</i> = 782 | French people | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 30.2 ± 6.1 | 29.2 ± 6.3 |
| | | | BMI (kg/m ²) | 23.9 ± 3.0 | 22.5 ± 3.4 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Janssen et al. (2004) | Valhalla 1990B Bio-Resistance Body Composition Analyzer | SMI moderate and severe sarcopenia men: 8.51–10.75 kg/m ² and ≤8.50 kg/m ² women: 5.76–6.75 kg/m ² and ≤5.75 kg/m ² SM by Janssen et al. (2000) equation | <i>n</i> = 4499 | US population (non-Hispanic White, non-Hispanic Black and Mexican American) | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 70.0 ± 7.0 | 71.0 ± 8.0 |
| | | | BMI (kg/m ²) | 26.6 ± 4.3 | 27.0 ± 5.5 |
| | | | → receiver operating characteristics | | |

ASMI, appendicular skeletal muscle mass index; BIA, bioelectrical impedance analysis; BMI, body mass index; FFM, fat-free mass; NA, not available; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index.

Table 3. Cut-off values and diagnostic criteria of a low muscle mass using computed tomography (CT).

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | |
|------------------------|--|--|---|---|
| Ufuk & Herek (2019) | lumbar CT images (16-detector row, Brilliance) | CT L3 SMI men: 44.98 cm ² /m ² women: 36.05 cm ² /m ² | <i>n</i> = 270 | healthy Turkish population |
| | | CT L3 PMI men: 2.63 cm ² /m ² women: 2.02 cm ² /m ² | <i>n</i> | men 134 44.3 ± 11.2 26.4 ± 3.5 → 2 SDs below the sex-specific means of young adults |
| Derstine et al. (2018) | lumbar CT images (GE Discovery or LightSpeed scanner) | (a) CT L3 SMI men: 45.4 cm ² /m ² women: 34.4 cm ² /m ² | (a) <i>n</i> = 727 | healthy US population |
| | | | <i>n</i> | men 317 18 to 40 NA → 2 SDs below the sex-specific means of young adults |
| | | (b) CT T10 SMI men: 28.8 cm ² /m ² women: 20.4 cm ² /m ² | (b) <i>n</i> = 278 | healthy US population |
| | | | <i>n</i> | men 122 18 to 40 NA → 2 SDs below the sex-specific means of young adults |
| | | (c) CT T11 SMI men: 27.6 cm ² /m ² women: 19.2 cm ² /m ² | (c) <i>n</i> = 577 | healthy US population |
| | | | <i>n</i> | men 241 18 to 40 NA → 2 SDs below the sex-specific means of young adults |
| | | (d) CT T12 SMI men: 28.8 cm ² /m ² women: 20.8 cm ² /m ² | (d) <i>n</i> = 700 | healthy US population |
| | | | <i>n</i> | men 299 18 to 40 NA → 2 SDs below the sex-specific means of young adults |
| | | (e) CT L1 SMI men: 34.6 cm ² /m ² women: 25.9 cm ² /m ² | (e) <i>n</i> = 724 | healthy US population |
| | | | <i>n</i> | men 315 18 to 40 NA → 2 SDs below the sex-specific means of young adults |

Table 3. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|----------------------------|--|---|---|------------------------------|------------|
| | | | (f) n = 726 | healthy US population | |
| | | (f) CT L2 SMI | | men | women |
| | | men: 40.1 cm ² /m ² | n | 315 | 411 |
| | | women: 30.4 cm ² /m ² | Age (year) | 18 to 40 | 18 to 40 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| | | | (g) n = 704 | healthy US population | |
| | | (g) CT L4 SMI | | men | women |
| | | men: 41.3 cm ² /m ² | n | 305 | 399 |
| | | women: 34.2 cm ² /m ² | Age (year) | 18 to 40 | 18 to 40 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| | | | (h) n = 506 | healthy US population | |
| | | (h) CT L5 SMI | | men | women |
| | | men: 39.0 cm ² /m ² | n | 211 | 295 |
| | | women: 30.6 cm ² /m ² | Age (year) | 18 to 40 | 18 to 40 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| van der Werf et al. (2018) | lumbar CT images (64-row CT scanner, Sensation 64, Siemens or CT Brilliance 64, Philips) | CT L3 SMI men: 44.6 cm ² /m ² women: 34.0 cm ² /m ² | n = 300 | healthy Caucasian population | |
| | | | | men | women |
| | | | n | 126 | 174 |
| | | | Age (y) | 20 to 60 | 20 to 60 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 5th percentile | | |
| Benjamin et al. (2017) | lumbar CT images (Discovery 750 HD 64-row spectral CT scanner) | CT L3 SMI men: 36.54 cm ² /m ² women: 30.21 cm ² /m ² | n = 275 | healthy Asian Indians | |
| | | | | men | women |
| | | | n | 139 | 136 |
| | | | Age (year) | 32.2 ± 9.8 | 32.2 ± 9.8 |
| | | | BMI (kg/m ²) | 24.2 ± 3.2 | 24.2 ± 3.2 |
| | | | → 2 SDs below the sex-specific means of young adults | | |

Table 3. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|----------------------------|---|--|--|--------------------------|--------------|
| Kim et al. (2017) | lumbar CT images (64-slice multidetector CT scanner, Brilliance 64, Philips Healthcare) | CT L3 PMI men: 5.92 cm ² /m ² (20–39 y), 4.74 cm ² /m ² (40–49 y), 4.22 cm ² /m ² (50–59 y), 3.74 cm ² /m ² (60–69 y), 3.32 cm ² /m ² (70–89 y) women: 4.0 cm ² /m ² (20–39 y), 2.88 cm ² /m ² (40–49 y), 2.43 cm ² /m ² (50–59 y), 2.20 cm ² /m ² (60–69 y), 1.48 cm ² /m ² (70–89 y) | <i>n</i> = 1422 | study performed in Korea | |
| | | | <i>n</i> | men | women |
| | | | 550 | 872 | |
| | | | Age (year) | 52.4 ± 12.0 | 53.3 ± 12.2 |
| | | | BMI (kg/m ²) | 24.5 ± 3.1 | 22.8 ± 3.2 |
| | | | total <i>n</i> for men and women depends on age range → 2 SDs below the sex-specific means of young, healthy adults | | |
| Sakurai et al. (2017) | lumbar CT images | CT L3 SMI men: 43.2 cm ² /m ² women: 34.6 cm ² /m ² | <i>n</i> = 569 patients with gastric cancer | study performed in Japan | |
| | | | <i>n</i> | men | women |
| | | | 396 | 173 | |
| | | | Age (year) | 66.7 ± 11.2 | 66.7 ± 11.2 |
| | | | BMI (kg/m ²) | 22.0 ± 3.4 | 22.0 ± 3.4 |
| | | | → lowest sex-specific quartile | | |
| Hamaguchi et al. (2016) | lumbar CT images (Aquilion 64, Toshiba Medical Systems) | CT L3 PMI men: 6.36 cm ² /m ² women: 3.92 cm ² /m ² | <i>n</i> = 230 | healthy Asian population | |
| | | | <i>n</i> | men | women |
| | | | 116 | 114 | |
| | | | Age (year) | 20 to 49 | 20 to 49 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| Zhuang et al. (2016) | lumbar CT images | CT L3 SMI men: 40.8 cm ² /m ² women: 34.9 cm ² /m ² | <i>n</i> = 937 patients with gastric cancer | study performed in China | |
| | | | <i>n</i> | men | women |
| | | | 730 | 207 | |
| | | | Age (year) | 64.0 ± 15.0 | 64.0 ± 15.0 |
| | | | BMI (kg/m ²) | 21.9 ± 3.0 | 21.9 ± 3.0 |
| | | | → optimal stratification | | |
| Iritani et al. (2015) | lumbar CT images | CT L3 SMI men: 36.0 cm ² /m ² women: 29.0 cm ² /m ² | <i>n</i> = 217 patients with hepatocellular carcinoma | study performed in Japan | |
| | | | <i>n</i> | men | women |
| | | | 146 | 71 | |
| | | | Age (year) | 27 to 90 | 27 to 90 |
| | | | BMI (kg/m ²) | 13.4 to 35.9 | 13.4 to 35.9 |
| | | | → optimal stratification | | |

BMI, body mass index; CT, computed tomography; L, lumbar vertebra; L3, third lumbar vertebra; NA, not available; PMI, psoas muscle index; SD, standard deviation; SMI, skeletal muscle mass index; T, thoracic vertebra.

Combination of Measures for Muscle mass and Obesity

Table 4 shows reference values of 34 publications for a low SM in combination with different measures of obesity. Cut-offs for a low SM were mostly determined by DXA or BIA, whereas only a few studies reported CT-defined cut-offs in combination with obesity criteria. SM parameters were commonly normalized for height squared or given as % of body weight. In addition, two studies adjusted ASM for BMI [66,67]. Alternative parameters were FM/FFM ratio [68], visceral fat area/thigh muscle area ratio (VFA/TMA) [69] and fat mass index (FMI) in combination with fat-free mass index (FFMI) [70].

Prado et al. [71] published CT-derived SMI cut-offs determined in a population of obese (BMI ≥ 30 kg/m²) Canadians with tumors of the respiratory or gastrointestinal tract. In 2013, this CT database was extended by Martin et al. [72] and low SM reference values were reported for subjects with normal weight and overweight according to BMI classifications. In both studies, optimal stratification was used to determine the threshold of mortality. Many studies adopted the criteria proposed by Prado et al. [71] and Martin et al. [72] (e.g., [73–75]). Only one further study developed BMI-dependent reference values for SM [76]. Although some studies referenced the cut-offs by Prado et al. [71], reported thresholds differ from the original work (e.g., [77,78]). These reported values were then cited in further studies [79].

In most studies, obesity was defined as BMI ≥ 30 kg/m² [71,76,80,81]. Alternative BMI thresholds were 27.5 kg/m² [82,83], 27 kg/m² [84], 25 kg/m² [72,85–90] or 23 kg/m² [91]. Furthermore, sex and ethnic-specific waist circumference (WC) thresholds for central obesity were considered [44,84,92–95]. Other criteria include %FM [50,81,96–101], visceral fat area [73] or fat-muscle ratios like visceral fat area (VFA) to total abdominal muscle area (TAMA) [74].

Table 5 displays cut-offs and average values for body composition stratified into groups of subjects with underweight, normal weight, overweight and obesity. Cut-offs for FMI_{DXA} were released by the National Health and Nutrition Examination Survey (NHANES; [102]) and respective BMI-dependent normal values for FFMI_{DXA} were calculated as BMI minus FMI. For each given BMI displayed in Table 5, corresponding normal value for SMI_{MRI} were calculated using a stepwise regression analysis (SMI_{MRI}, men = $0.479 \times \text{FFMI}_{\text{DXA}} - 0.017 \times \text{age} + 0.683$ and SMI_{MRI}, women = $0.348 \times \text{FFMI}_{\text{DXA}} - 0.011 \times \text{age} + 1.971$) in a healthy Caucasian population. In addition, respective values for SMI_{BIA} validated against MRI were generated based on a young and healthy Caucasian population using linear regression analysis (SMI_{BIA}, men = $0.168 \times \text{BMI} + 5.49$ ($R^2 = 0.53$, standard error of estimate (SEE) = 0.514) and SMI_{BIA}, women = $0.159 \times \text{BMI} + 3.72$ ($R^2 = 0.61$, SEE = 0.465)). Adjacent to the average SMI_{BIA} (median) for each BMI, cut-offs with two SDs below the sex-specific mean of the young and healthy population were shown.

Table 4. Cut-off values that combine measures of muscle mass and obesity.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|---------------------------|--------------------------|--|--|-------------|---------------------------|
| Prado et al. (2008) | CT images | CT L3 SMI: men: ≤52.4 cm ² /m ² women: ≤38.5 cm ² /m ² + BMI ≥ 30 kg/m ² | <i>n</i> = 250 obese patients with cancers of the respiratory tract and gastrointestinal locations | | study performed in Canada |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 64.6 ± 10.2 | 63.2 ± 10.5 |
| | | | BMI (kg/m ²) | 33.9 ± 4.4 | 34.7 ± 4.3 |
| | | | → optimal stratification | | |
| Martin et al. (2013) | CT images | CT L3 SMI: men: <43 cm ² /m ² women: <41 cm ² /m ² for BMI < 25 kg/m ² men: <53 cm ² /m ² for BMI ≥ 25 kg/m ² | <i>n</i> = 1473 patients with cancers of the respiratory tract and gastrointestinal locations | | study performed in Canada |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 64.7 ± 11.2 | 64.8 ± 11.5 |
| | | | BMI (kg/m ²) | 26.0 ± 4.9 | 25.1 ± 5.8 |
| | | | → optimal stratification | | |
| Muscariello et al. (2016) | BIA (RJL 101, Akern SRL) | (a) SMI + BMI < 25 kg/m ² Class I and Class II sarcopenia women: 7.4 and 6.8 kg/m ² | (a) <i>n</i> = 313 | | study performed in Italy |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 0 | 313 |
| | | | BMI (kg/m ²) | | 28.5 ± 7.6 |
| | | | → Class I sarcopenia: 1 SD below the sex-specific means of young adults | | |
| | | | → Class II sarcopenia: 2 SDs below the sex-specific means of young adults | | |
| | | (b) SMI + BMI ≥ 30 kg/m ² Class I and Class II sarcopenia women: 8.3 and 7.3 kg/m ² SM by Janssen et al. (2000) equation | (b) <i>n</i> = 361 | | study performed in Italy |
| | <i>n</i> | | men | women | |
| | Age (year) | | 0 | 361 | |
| | BMI (kg/m ²) | | | 30.9 ± 7.9 | |
| | | | → Class I sarcopenia: 1 SD below the sex-specific means of young adults | | |
| | | | → Class II sarcopenia: 2 SDs below the sex-specific means of young adults | | |
| Nishigori et al. (2016) | CT images | CT L3 SMI (Prado et al. 2008): men: ≤52.4 cm ² /m ² women: ≤38.5 cm ² /m ² + visceral fat area (VFA) ≥100 cm ² in both sexes | reference group characteristic CT L3 SMI see Prado et al. (2008) | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|------------------------------|--|---|--|--------------------------|-------------|
| Pecorelli et al. (2016) | CT images | (a) CT L3 SMI (Prado et al. 2008): men: ≤52.4 cm ² /m ² women: ≤38.5 cm ² /m ² + | (a) reference group characteristic CT L3 SMI see Prado et al. (2008) | | |
| | | (b) visceral fat area/total abdominal muscle area ratio (VFA/TAMA) men & women: 3.2 | (b) n = 202 patients with resectable pancreas, periampullary | study performed in Italy | |
| | | | n | men | women |
| | | | Age (year) | 108 | 94 |
| | | | BMI (kg/m ²) | 66.8 ± 10.7 | 66.8 ± 10.7 |
| | | | | 23.6 ± 3.7 | 23.6 ± 3.7 |
| | | | → optimal stratification | | |
| Kwon et al. (2017) | DXA (Discovery QDR 4500, Hologic) | ASM (as % of body weight) | n = 3550 | Koreans | |
| | | men: 30.98% | n | men | women |
| | | women: 24.81% | Age (year) | 1668 | 1882 |
| | | BMI ≥ 25 kg/m ² (based on the definition in the Asian-Pacific region) | BMI (kg/m ²) | 20 to 39 | 20 to 39 |
| | | | → 1 SD below the sex-specific means of young adults | | |
| Chiles Shaffer et al. (2017) | DXA (Lunar Prodigy Advance with GE EnCore 2006 version 10.51.0006) | ASM adjusted for BMI | n = 545 | study performed in US | |
| | | men: <0.725 kg/m ² | n | men | women |
| | | women: <0.591 kg/m ² | Age (year) | 287 | 258 |
| | | | BMI (kg/m ²) | 79.2 ± 7.2 | 77.7 ± 7.3 |
| | | | | 27.2 ± 3.8 | 27.0 ± 5.2 |
| | | | → CART analysis | | |
| An & Kim (2016) | DXA (Discovery-W, Hologic) | ASM (as % of body weight) | n = 5944 | study performed in Korea | |
| | | men: 30.1% | n | men | women |
| | | women: 21.2% | Age (year) | 2502 | 3334 |
| | | WC ≥ 90 cm in men | BMI (kg/m ²) | 20 to 39 | 20 to 39 |
| | | WC ≥ 80 cm in women | → 1 SD below the sex-specific means of young adults | | |
| | | (sex-specific cut-off for Asians) | | NA | NA |
| Cho et al. (2015) | (a) DXA (Discovery-W, Hologic) | (a) ASM (as % of body weight) | (a) n = 4987 | Koreans | |
| | | men: 30.3% | n | men | women |
| | | women: 23.8% | Age (year) | 2123 | 2864 |
| | | WC ≥ 90 cm in men | BMI (kg/m ²) | 20 to 39 | 20 to 39 |
| | | WC ≥ 85 cm in women | → 1 SD below the sex-specific means of young, healthy adults | | |
| | | | | NA | NA |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|--------------------------|---|--|---|--------------------------|---------------|
| Oh et al. (2015) | DXA (Lunar Corp.) | ASM (as % of body weight) men: 44% women: 52% + BMI ≥ 25 kg/m ² | <i>n</i> = 1746 | Koreans | |
| | | | <i>n</i> | men 748 | women 998 |
| | | | Age (year) | 20 to 39 | 20 to 39 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 1 SD below the sex-specific means of young, healthy adults | | |
| Lee et al. (2015) | DXA (Discovery QDR 4500, Hologic) | ASM (as % of body weight) men: 32.2% women: 25.5% + BMI ≥ 25 kg/m ² (based on the criteria of the Asian-Pacific region) | <i>n</i> = 2200 | Koreans | |
| | | | <i>n</i> | men 960 | women 1240 |
| | | | Age (year) | 20 to 30 | 20 to 30 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 1 SD below the sex-specific means of young, healthy adults | | |
| Baek et al. (2014) | DXA (Lunar Corp.) | ASMI men: 6.96 kg/m ² women: 4.96 kg/m ² ASM (as % of body weight) men: 30.65% women: 23.90% + BMI ≥ 25 kg/m ² (IOTF-proposed classification of BMI for Asia) | <i>n</i> = 4192 | Koreans | |
| | | | <i>n</i> | men 1699 | women 2493 |
| | | | Age (year) | 20 to 39 | 20 to 39 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 1 SD below the sex-specific means of young, healthy adults | | |
| Cawthon et al. (2014) | DXA (QDR 4500, Hologic 2000, Lunar Prodigy) | ASM adjusted for BMI men: <0.789 women: <0.512 recommended by FNIH (Studenski et al., 2014) | <i>n</i> = 11,270 | study performed in US | |
| | | | <i>n</i> | men 7582 | women 3688 |
| | | | Age (year) | 65 to 80 | 65 to 80 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → CART analysis plus sensitivity analyses | | |
| Chung et al. (2013) | (a) DXA (fan-beam technology, Lunar Corp.) | (a) ASM (as % of body weight) men: 32.5% women: 25.7% + BMI ≥ 25 kg/m ² (IOTF-proposed classification of BMI for Asia) | (a) <i>n</i> = 2781 | study performed in Korea | |
| | | | <i>n</i> | men 1155 | women 1626 |
| | | | Age (year) | 20 to 39 | 20 to 39 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 1 SD below the sex-specific means of young, healthy adults | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|---------------------|-------------------------------|---|---|--------------------------|---------------|
| Hwang et al. (2012) | DXA (Discovery-W, Hologic) | ASM (as % of body weight) men: 29.53% women: 23.20% | <i>n</i> = 2269 | Koreans | |
| | | + WC ≥ 90 cm in men WC ≥ 85 cm in women (Korean abdominal obesity criteria; Lee et al., 2007) | <i>n</i> | men 1003 | women 1266 |
| | | | Age (year) | 30.7 ± 5.5 | 31.0 ± 5.5 |
| | | | BMI (kg/m ²) | 24.1 ± 3.5 | 22.1 ± 3.6 |
| | | | → 2 SDs below the sex-specific means of young adults | | |
| Lee et al. (2012) | DXA (Discovery-W, Hologic) | ASM (as % of body weight) men: 26.8% women: 21.0% | <i>n</i> = 2113 | Koreans | |
| | | + BMI ≥ 27.5 kg/m ² | <i>n</i> | men 902 | women 1211 |
| | | | Age (year) | 20 to 40 | 20 to 40 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Kim et al. (2012) | DXA (Discovery-W, Hologic) | ASM (as % of body weight) Class II sarcopenia men: 29.1% women: 23.0% | <i>n</i> = 2513 | Koreans | |
| | | ASMI Class II sarcopenia men: 6.58 kg/m ² women: 4.59 kg/m ² | <i>n</i> | men 1245 | women 1268 |
| | | + WC ≥ 90 cm in men (Lee et al., 2007) WC ≥ 85 cm in women | Age (year) | 31.0 ± 5.5 | 30.8 ± 5.6 |
| | | | BMI (kg/m ²) | 24.0 ± 3.4 | 22.1 ± 3.5 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| Kim et al. (2011) | DXA (Lunar Corp.) | ASM (as % of body weight) men: 29.5% women: 23.2% | <i>n</i> = 2392 | study performed in Korea | |
| | | + BMI ≥ 27.5 kg/m ² | <i>n</i> | men 1054 | women 1338 |
| | | | Age (year) | 20 to 40 | 20 to 40 |
| | | | BMI (kg/m ²) | NA | NA |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|------------------------------|-------------------------------------|--|---|---|-------------|
| Kim et al. (2009) | DXA (Discovery A, Hologic) | (a) ASMI men: 8.81 kg/m ² women: 7.36 kg/m ² | <i>n</i> = 526 | Koreans | |
| | | + | <i>n</i> | men | women |
| | | (b) FM men: 20.21% women: 31.71% | Age (year) | 52.2 ± 14.4 | 51.2 ± 14.8 |
| | | | BMI (kg/m ²) | 25.2 ± 3.1 | 23.9 ± 3.7 |
| | | | → (a) lower two quintiles → (b) two highest quintiles | | |
| Rolland et al. (2009) | (a) DXA (Lunar DPX, Lunar Corp.) | (a) ASMI women: 5.45 kg/m ² (Baumgartner et al., 1998) | (a) <i>n</i> = 122 | US population (non-Hispanic white men and women) | |
| | | + | <i>n</i> | men | women |
| | | | Age (year) | | 29.7 ± 5.9 |
| | | | BMI (kg/m ²) | | 24.1 ± 5.4 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| | (b) DXA (QDR 4500 W, Hologic) | (b) FM women: 40% | (b) <i>n</i> = 1308 | study performed in France | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 0 | 1308 |
| | | | BMI (kg/m ²) | | ≥75 |
| | | | → 60th percentile of the healthy study sample | | |
| Baumgartner et al. (1998) | DXA (Lunar DPX, Lunar Corp.) | (a) ASMI men: 7.26 kg/m ² women: 5.45 kg/m ² | <i>n</i> = 229 | US population (non-Hispanic white men and women) | |
| | | + | <i>n</i> | men | women |
| | | (b) FM men: 27% women: 38% | Age (year) | 28.7 ± 5.1 | 29.7 ± 5.9 |
| | | | BMI (kg/m ²) | 24.6 ± 3.8 | 24.1 ± 5.4 |
| | | | (a) → 2 SDs below the sex-specific means of young, healthy adults (b) → >sex-specific median | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|---|-----------------------------------|---|---|--|------------|
| Bahat et al. (2016); Bahat et al. (2018) | BIA (Tanita-BC532) | (a) SMI men: 9.2 kg/m ² women: 7.4 kg/m ² SM (kg) = 0.566 × FFM + | (a) n = 301 | study performed in Turkey | |
| | | | n | men | women |
| | | | Age (year) | 26.8 ± 4.5 | 25.9 ± 4.7 |
| | | | BMI (kg/m ²) | 25.5 ± 3.6 | 22.4 ± 3.4 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| | | (b) FM men: 27.3% women: 40.7% | (b) n = 992 | study performed in Turkey | |
| | | | n | men | women |
| | | | Age (year) | 75.2 ± 7.2 | 75.2 ± 7.2 |
| | | | BMI (kg/m ²) | 27.7 ± 4.3 | 30.7 ± 5.6 |
| | | | → above 60th percentile | | |
| Ishii et al. (2016) | (a) BIA (Tanita MC-190) | (a) ASMI men: 7.0 kg/m ² women: 5.8 kg/m ² + | (a) n = 1719 | Japanese | |
| | | | n | men | women |
| | | | Age (year) | 26.6 ± 6.7 | 28.5 ± 7.3 |
| | | | BMI (kg/m ²) | 22.4 ± 3.2 | 20.8 ± 2.9 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| | (b) BIA (InBody 430, Biospace) | (b) FM men: 29.7% women: 37.2% | (b) n = 1731 | Japanese | |
| | | | n | men | women |
| | | | Age (year) | 875 | 856 |
| | | | BMI (kg/m ²) | ≥ 65 | ≥ 65 |
| | | | | NA | NA |
| | | | → highest quintile | | |
| Moreira et al. (2016) | BIA (InBody R20, Biospace) | ASMI women: 6.08 kg/m ² + | n = 491 | study performed in Northeast Brazil (Whites, Blacks, Pardo) | |
| | | WC ≥ 88 cm in women (Brazilian obesity guidelines) | n | men | women |
| | | | Age (year) | 0 | 491 |
| | | | BMI (kg/m ²) | | 50.0 ± 5.6 |
| | | | | | 29.0 ± 4.8 |
| | | | → 20th percentile | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|-----------------------|---|---|---|---|-------------|
| Kemmler et al. (2016) | BIA (InBody 770, Biospace) | (a) ASMI women: 5.66 kg/m ² | (a) <i>n</i> = 689 | study performed in Germany (Caucasians) | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 0 | 689 |
| | | | BMI (kg/m ²) | | 18 to 35 |
| | | | → 2 SDs below the sex-specific means of young, healthy adults | | |
| | | (b) ASMI women: 5.99 kg/m ² | (b) <i>n</i> = 1325 | study performed in Germany (Caucasians) | |
| | | + BMI ≥ 30 kg/m ² (NIH) | <i>n</i> | men | women |
| | | + FM ≥ 35% (WHO) | Age (year) | 0 | 1325 |
| | | | BMI (kg/m ²) | | 76.4 ± 4.9 |
| | | | | | 26.7 ± 4.3 |
| | | | | → lowest quintile | |
| Lee et al. (2016) | BIA (InBody 720, Biospace) | (a) SMI (as % of body weight) men: 38.2 % women: 32.2% SM by Janssen et al. (2000) equation + | (a) <i>n</i> = 273 | study performed in Korea | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 157 | 116 |
| | | | BMI (kg/m ²) | 25.5 ± 2.9 | 26.1 ± 4.6 |
| | | | | 24.1 ± 3.0 | 20.7 ± 2.6 |
| | | | | → 2 SDs below the sex-specific means of young, healthy adults | |
| | | (b) <i>n</i> = 309 | study performed in Korea | | |
| | | (b) FM men: 25.8% women: 36.5% | <i>n</i> | men | women |
| | | | Age (year) | 85 | 224 |
| | | | BMI (kg/m ²) | 70.7 ± 6.3 | 66.4 ± 7.2 |
| | | | | NA | NA |
| | | | | → two highest quintiles | |
| Biolo et al. (2015) | BIA (Human IM-Plus, DS, Dieto System, BIA 101, Akern Srl, Tanita BC418MA, Tanita Corp.) | FM/FFM ratio > 0.8 | <i>n</i> = 200 | study performed in Italy and Slovenia | |
| | | | <i>n</i> | men | women |
| | | | Age (year) | 89 | 111 |
| | | | BMI (kg/m ²) | 48.0 ± 12.0 | 51.0 ± 12.0 |
| | | | | 35.6 ± 6.2 | 35.5 ± 5.4 |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|-----------------------------|--------------------------------------|--|---|--|---|
| De Rosa et al. (2015) | BIA (Human IM Plus II-DS Medical) | SMI moderate and severe sarcopenia men: 8.44–9.53 kg/m ² and ≤8.43 kg/m ² women: 6.49–7.32 kg/m ² and ≤6.48 kg/m ² | <i>n</i> = 500 | Italians | |
| | | SMI (as % of body weight) moderate and severe sarcopenia men: 28.8–35.6% and ≤28.7% women: 23.1–28.4% and ≤23.0% SM by Janssen et al. (2000) equation + BMI ≥ 30 kg/m ² | <i>n</i> Age (year) BMI (kg/m ²) | men 100 27.0 ± 7.0 25.8 ± 5.7 | women 400 25.0 ± 6.0 25.2 ± 5.7 |
| Atkins et al. (2014) | BIA (Bodystat 500, Bodystat Ltd.) | FFMI men: ≤16.7 kg/m ² FFM (equation by Deurenberg et al., 1991) + FMI > 11.1 kg/m ² | <i>n</i> = 4045 | study performed in UK (> 99 % white Europeans) | |
| | | | <i>n</i> Age (year) BMI (kg/m ²) | men 4045 60 to 79 NA | women 0 |
| | | | → lowest two-fifths of FFMI | | |
| Baek et al. (2013) | BIA (InBody 520, Biospace) | ASMI men: 10.70 kg/m ² women: 8.60 kg/m ² + BMI > 25 kg/m ² (WHO definition) | <i>n</i> = 1150 | study performed in Korea | |
| | | | <i>n</i> Age (year) BMI (kg/m ²) | men 618 43.6 ± 11.5 24.6 ± 3.3 | women 532 43.6 ± 11.5 24.6 ± 3.3 |
| | | | → 50th percentile of healthy study sample | | |
| Gomez-Cabello et al. (2011) | BIA (Tanita BC 418-MA) | (a) SMI men: 8.61 kg/m ² women: 6.19 kg/m ² (b) FM men: 30.33% women: 40.9% SM by Janssen et al. (2000) equation | <i>n</i> = 3136 | Spaniards | |
| | | | <i>n</i> Age (year) BMI (kg/m ²) | men 678 72.4 ± 5.5 NA | women 2198 72.1 ± 5.2 NA |
| | | | → (a) two lower quintiles → (b) two highest quintiles | | |

Table 4. Cont.

| Reference | Device/Software | Parameter/Cut-Off by Gender | Reference Group Characteristics (Mean ± SD)/Diagnostic Criteria (→) | | |
|----------------------------|---|--|---|--|--|
| Lou et al. (2017) | CT images | CT L3 SMI (Zhuang et al., 2016) men: ≤40.8 cm ² /m ² women: ≤34.9 cm ² /m ² + BMI ≥ 23 kg/m ² (WHO definition for Asians) | Predefined cut-off values for sarcopenia and obesity | | |
| Ramachandran et al. (2012) | CT images (Somatom Sensation 10 CT scanner) | adjusted thigh muscle area: men: 110.7 cm ² women: 93.8 cm ² + (1) BMI ≥ 27 kg/m ² (2) WC ≥ 102 cm for men WC ≥ 88 cm for women | n = 539 n Age (year) BMI (kg/m ²) | study performed in US men 280 71.1 ± 0.4 NA → lowest sex-specific tertile | |
| Lim et al. (2010) | CT images (Brilliance 64, Philips) | Visceral fat area (VFA)/thigh muscle area (TMA) men: 0.93 women: 0.90 | n = 264 n Age (year) BMI (kg/m ²) | Koreans men 126 20 to 88 NA → VFA/TMA median higher 50th percentile of the healthy study sample | |

ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal muscle mass index; BMI, body mass index; BIA, bioelectrical impedance analysis; CART, classification and regression tree analysis; CT, computed tomography; DXA, dual X-ray absorptiometry; FFM, fat-free mass; FFMI, fat-free mass index; FM, fat mass; FMI, fat mass index; FNIH, Foundation for the National Institutes of Health; IOTF, International Obesity Taskforce; L3, third lumbar vertebra; NA, not available; NIH, National Institutes of Health; SD, standard deviation; SM, skeletal muscle mass; SMI, skeletal muscle mass index; TAMA, total abdominal muscle area; TMA, thigh muscle area; VFA, visceral fat area; WC, waist circumference; WHO, World Health Organization.

Table 5. Generation of cut-offs for SMI (corresponding to BMI thresholds) based on FFMI.

| | BMI (kg/m ²) | FMI _{DXA} (kg/m ²) (Kelly et al., 2009) | FFMI _{DXA} (kg/m ²) (Modified according to Kelly et al., 2009) | SMI _{MRI} (kg/m ²) (1.5 T Siemens Avanto MRI Scanner) | SMI _{BIA_median} (kg/m ²) (mBCA 515, Seca) | SMI _{BIA_-2SDs} (kg/m ²) (mBCA 515, Seca) |
|--------------------|-----------------------------|---|---|--|---|---|
| Caucasian men | <18.5 | <2.9 | 15.6 | | 8.6 | >7.6 |
| | >25 | >6.0 | 19.0 | 9.85 | 9.7 | >8.7 |
| | >30 | >8.9 | 21.1 | 10.71 | 10.5 | >9.5 |
| | >35 | >11.9 | 23.1 | 12.15 | 11.4 | >10.3 |
| | >40 | >15.0 | 25.0 | 13.67 | 12.2 | >11.2 |
| Caucasian women | <18.5 | <4.9 | 13.6 | 6.65 | 6.7 | >5.7 |
| | >25 | >9.2 | 15.8 | 7.49 | 7.7 | >6.8 |
| | >30 | >12.9 | 17.1 | 8.15 | 8.5 | >7.6 |
| | >35 | >16.8 | 18.2 | 8.99 | 9.3 | >8.4 |
| | >40 | >20.6 | 19.4 | 9.74 | 10.1 | >9.2 |

BMI, body mass index; FMI_{DXA}, fat mass index by dual X-ray absorptiometry (QDR 4500A fan beam densitometer (Hologic, Inc., Bedford, MA, Hologic Discovery software version 12.1)); FFMI_{DXA}, fat-free mass index by dual X-ray absorptiometry; SMI_{MRI}, skeletal muscle mass index by magnetic resonance imaging calculated by stepwise regression analysis ($n = 410$, 219 women (age: 38 ± 13 years, BMI: 27.7 ± 6.5 kg/m²) and 191 men (age: 41 ± 14 years, BMI: 27.7 ± 5.0 kg/m²) (detailed description of the segmentation procedure given elsewhere (Schutz et al., 2012)); SMI_{BIA_median}, skeletal muscle mass index by bioelectrical impedance analysis given as median calculated by linear regression analysis ($n = 529$, 264 women (27 ± 6 years, BMI: 23.9 ± 3.6 kg/m²) and 265 men (28 ± 6 years, BMI: 25.2 ± 3.2 kg/m²) (detailed description of the BIA measurement procedure given elsewhere (Bosy-Westphal et al., 2017)); SMI_{BIA_-2SDs}, skeletal muscle mass index by bioelectrical impedance analysis given as 2 SDs below the sex-specific mean calculated as linear regression analysis.

4. Discussion

SM has evolved as the most promising body composition parameter associated with health risk in ageing and many chronic diseases [1]. Evaluation of SM is complicated by a variety of available methods that provide different outcome parameters as a proxy for total body SM. Therefore, it is important to have accurate reference values that apply to the patient or population under study as well as to the respective body composition method. In this review, we identified multiple published reference values for discrepant parameters of SM (Tables 1–4), discussed the differences in the underlying assumptions and limitations as well as different concepts for normalization of SM parameters for height, weight, BMI or FM.

Imaging technologies are thought to provide the best assessment of SM. Briefly, segmentation of transversal images by special software (e.g., SliceOmatic Tomovision, version 4.3; Montreal, Québec, Canada) results in muscle areas that are multiplied by the correspondent slice thickness to calculate muscle volume [27] that is transformed to SM by assuming a constant density (1.04 kg/L) of adipose tissue-free SM [103]. Muscles at the head, hands and feet are commonly neglected in this approach. The precision of whole body SM_{MRI} is high (intra-observer coefficient of variation = 1.8% [104]). Reference data for total SM based on the gold standard whole body MRI (Table 5) are scarce due to high costs and cumbersome image-segmentation [17,18]. However, whole body MRI was integrated in the assessment of current large and representative national databases like the UK biobank [105] or the national cohort (NAKO) in Germany [106]. Future evaluation of these databases will provide the basis of statistically derived normal values whereas prospective investigation of mortality or correlation with frailty, fracture risk, glucose or amino acid metabolism would allow to establish even more meaningful disease-specific cut-offs.

Instead of whole body imaging, reference values for L3 single slices are frequently published (Tables 3 and 4), especially in patients where CT images are routinely applied for cancer staging. The use of these cut-offs may be specific for the population studied and transferability of the results to other patient groups needs to be investigated. Radiation exposure is a major limitation that confines the application of CT to individual transversal images or the secondary analysis of routine clinical measurements. As a further drawback, clinical CT protocols for L3 are not standardized across hospital sites. SMA at L1, L2, L4, L5, and the thoracic vertebra T12, T11, and T10 were reported to be suitable alternatives to SMA measured at L3 [58]. Nonetheless, there are also advantages of CT images with a high resolution and precision of the measurement. Most studies report the precision of single slice CT scan analysis to range between 1% and 2% [107]. Thus, automated segmentation is facilitated by using a characteristic range of Hounsfield units for fat-free muscle tissue [107,108]. CT can also differentiate individual muscle or muscle groups and can thus for example investigate the impact of pectoralis muscle area for survival at the Intensive Care Unit [12] because respiratory musculature may determine weaning from mechanical ventilation. On the other hand, characteristic changes in the Hounsfield distribution of muscle can reveal qualitative changes of the tissue (e.g., fatty infiltration or edema) that have been found to be of prognostic value [71].

DXA is the most commonly used method for assessment of SM (Table 1). Lean soft tissue at the arms and legs (ASM) is highly correlated with muscle volume derived from imaging studies (correlation coefficients ranging from 0.77 to 0.97 for both, whole body and regional scans [51,109–115]). However, only 44% of total lean soft tissue is derived from extremities (unpublished results) and only part of total lean soft tissue is SM. Therefore, SM measured by DXA is considerably higher when compared with muscle volume measured by imaging technologies [27,116]. Precision errors for total ASM are reported to be low (1–3%), device specific and depend on population characteristics like age or prevalence of obesity [117].

BIA can assess SM, ASM or FFM, depending on the reference method used to generate the BIA-algorithm. The choice of the BIA-algorithm not only depends on the desired target-parameter but also on the agreement between the BIA-device or reference population used to generate the BIA-algorithm and the BIA-device and patient characteristics to be evaluated [118]. However, in two

studies, the equation by Janssen et al. [56] that is not suitable for Asians was used to predict SM in Asian populations [53,55] with only one study providing a validation in 41 Taiwanese people (age: 20–99 years; BMI: 17.6–34.6 kg/m²) [55]. Except for the study by Masanés et al. [26], all other studies used different BIA devices than Janssen et al. [56] (Table 2). Validity and precision of BIA results differ between manufacturers and depend on the hardware as well as the appropriate validation of the BIA-algorithm [119]. Discrepancies in the assumptions of the homogeneous bioelectrical model that lead to a higher measurement error occur with changes in hydration (e.g., edema) and with differences in body shape that are associated with aging (decreasing limb relative to trunk diameter), obesity (apple and pear shape of body fat distribution) and ethnicity (trunk to leg length, regional adiposity and muscularity). Therefore, segmental BIA that can measure the relative contribution of trunk and extremities to total body conductivity may help to reduce assumptions on body shape leading to an improved prediction compared with conventional wrist-ankle measurements [27]. The accuracy of phase-sensitive segmental BIA compared with MRI as a reference is clinically acceptable when whole body SM was assessed (two SDs: 11–12% for different ethnicities) but it was low when small compartments of the body were assessed (e.g., two SDs: 20–29% for the arms) [27].

4.1. Limitations of Proxies for Total Skeletal Muscle

Single SMA at L3 level turned out to be the best compromise site to assess volumes of total SM together with visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) ($r = 0.832$ – 0.986 ; $p < 0.01$ [17]). Furthermore, SMA at L3 is considered as a valid proxy for whole body FFM ($r = 0.940$; $p < 0.001$ [120]). Other authors reported high correlations between single abdominal SMA at L4–L5 intervertebral space and total SM ($r = 0.710$ – 0.920 [121]), whereas the use of PMI to determine whole body SM is controversial because psoas is a relatively small muscle. A good correlation between PMI and SMI measured by BIA in healthy 35 Asian liver donors ($r = 0.737$; $p < 0.001$) and a moderate correlation in 137 living donor liver transplantation recipients ($r = 0.682$; $p < 0.001$) were found [63]. Other authors argue that L3 PMA is not representative of total SM [122,123]. Despite acceptable correlations, the accuracy of single images is limited in individual cases. Likewise, it is well established that the correlation between BMI and FM is fairly good at the population level whereas at the individual level BMI is only a poor indicator of adiposity [124]. In addition, validity of the assessment of changes in SM during follow-up is limited by the use of individual images from L3 or mid-thigh. These images cannot be used as pars pro toto because of regional differences in changes of muscle volume with age or obesity (e.g., the contribution of SM_{MRI} at the arms and legs to ASM tended to decrease at higher adiposity in both genders [104]).

Similarly, ASM has limitations to assess the change in total SM with ageing or overweight and obesity. Since lean soft tissue from the extremities also contains lean compartments from connective tissue (e.g., skin and adipose tissue), SM accounts for only about 50% of FFM in obesity [116]. ASM was therefore shown to overestimate appendicular SM assessed by MRI with increasing BMI [27]. In line with this finding, DXA was also shown to underestimate the age-related loss of thigh muscle mass in comparison with MRI [125]. Furthermore, DXA measures of change in lean mass before and 10-week after resistance training were only modestly associated with MRI measures of change in muscle volume [126].

In summary, the random error of single images or ASM as a proxy for total SM limits the applicability of these substitutes in individual cases and together with the systematic error limit the accurate detection of changes in SM.

4.2. Normalization of Skeletal Muscle Mass for Body Size and Obesity

Normalization of lean mass for weight is inappropriate because two people with the same %FFM who differ in height have a different nutritional status, with the taller person having a lower muscularity [127]. FFM has been shown to scale to height with a power of around two in different

ethnicities, ranging from 1.86 in non-Hispanic white women to 2.32 in non-Hispanic black men [128]. Consequently, appropriate normalization of total SM, SM-area, ASM and FFM is performed for height².

In addition to the physiologic increase in SM with height, there is also an increase in SM with weight gain that depends on the initial amount of FM [129]. The evaluation of SM may thus also depend on the amount of FM. With increasing obesity, adverse effects on myocyte metabolism, muscle tissue composition and peak force generation can be mediated via paracrine signaling of proinflammatory immune cells in intermuscular adipose tissue [30]. The same SM at a higher FM may also lead to a limitation of strength and increased disability because at the same work load, energy expenditure and muscle force are higher for a person with obesity [130]. In line with these mechanisms, patients with a low SM and a concomitant high FM were shown to have a higher morbidity and mortality when compared to patients with a high FM only (for review see [131]). However, it remains unclear whether the risk of a low SM and a high FM is additive or if the risk of a high FM is disproportionately higher at a concomitantly low SM.

Published definitions of sarcopenic obesity use BMI to assess overweight and obesity in combination with fixed cut-offs for a low SM that are derived from subjects with normal weight and/or overweight [72,76]. To the best of our knowledge, all current definitions disregard the relationship between fat and lean mass that can be investigated by applying the Forbes rule (energy partitioning, i.e., the fraction of energy lost or gained as protein, is a nonlinear function of FM [129]) or the Hattori chart (two dimensional plot of FMI vs. FFMI [132]). Table 5 provides novel BMI-dependent SMI cut-offs.

The combination of FFMI with FMI [133], %FM [6,8] or BMI [134] facilitate to investigate the proportional contribution of fat and lean compartments to health risk as well as their presumable interaction. An attractive alternative to the simultaneous use of two indices is integration of information on fat and lean compartments in one index as FM/FFM². This index was proposed by Wells and Victoria who determined the appropriate power by which to raise the denominator from regressing FM on FFM [135]. The usefulness of this index needs to be investigated in future studies because it depends on a linear correlation between FM and FFM², as well as on absence of heteroscedasticity.

Beyond diverse methods of normalization (e.g., appendicular lean mass (ALM) adjusted by BMI [66,67], FFM normalized for body surface area ($FFM_{BSA} = (\text{weight [kg]}^{0.425} \times \text{height [m]}^{0.725}) \times 0.007184$ [20])) heterogeneous outcome parameters (ASMI, SMI, L3 SMI, L3 PMI, FFMI) and a discrepant nomenclature for the same outcome parameter as well as different ways of reporting reference values hinder the comparison between studies. ASMI (i.e., appendicular skeletal muscle mass/height²) and SMI (total skeletal muscle mass/height²) were the most commonly used denominations within publications and therefore consistently applied in Tables 1–5. A great variety of different notations for the same outcome parameter were found for (a) SMI: e.g., skeletal muscle mass index, SMMI [52], muscle mass index, MMI [25,26], total skeletal muscle index, TSMI [53], total body skeletal muscle mass index, TBSMI [40] and also (b) ASMI: e.g., appendicular skeletal muscle mass index, ASMMI [136], appendicular muscle mass index, AMI (appendicular muscle mass (AMM)/height²) [54], relative appendicular skeletal muscle index, RASM [47,137], relative skeletal muscle mass index [138] and appendicular lean mass index (ALM/height²) [21]. In contrast to the heterogeneous nomenclature, some studies apply the same term “SMI” for different outcome parameters: e.g., ALM/BMI [66,67], ASM/height² [46,139,140], ALM/height² [141], ASM/body weight [53] and SM/body weight $\times 100$ [25,137,142–144]. In cancer studies, SMI is normally defined as SMA/height² [62,71,72]. Thus, a consistent nomenclature for proxies of SM is needed in order to facilitate comparison between studies.

Moreover, suitable reference values require an appropriate sample size ideally comprised of healthy or “normal” subjects (normative approach) or derive cut-offs from an older population or a group of patients (stratification approach). In addition, reference values can be reported using parametric methods, like Z-scores or 2 SDs below the mean, that rely on normal distribution of the data, on the absence of residual associations, and on constant variance of the normalized measurements throughout the entire sample (absence of heteroscedasticity, logarithmic transformation of the dependent variables

or weighted regression models). In Tables 1–4, most studies used cut-off thresholds for low SM on the basis of young healthy adults' reference groups according to the recommendations proposed by the European Working Group on Sarcopenia in Older People [32]. The majority of these studies used two SDs below the means of healthy young subjects as a cut-off, e.g., [21,39,40,44,45,50] whereas other studies defined a low SM as one SD below the mean, e.g., [85,90,94,95]. Six articles stratified the cut-offs according to severity of a low SM [22,44,46,49,76,80]. One SM threshold was based on the fifth percentile [59] or on the 20th percentile [92] or on the 50th percentile [89]. Other studies used the sex-specific lowest quintiles [43], quartiles [47,62], tertiles [84], the lower two quintiles of the study population [98,100] or the lowest 20% of the distribution [38,42,48]. In one study, receiver operating characteristics analysis was used to develop SM cut-offs associated with physical disability [24]. In four studies, optimal stratification was used to determine the SM threshold of mortality risk in cancer patients [64,65,71,72]. Further diagnostic criteria applied classification and regression tree analysis [66,67].

5. Conclusions and Recommendations

In summary, published reference values for SM differ widely dependent on the outcome parameter and reference population. Results should consider the limitation of all proxies for total SM with respect to application in individual cases as well as for measurement of changes in SM. To facilitate comparison between results of different studies, authors should use a unified nomenclature for outcome parameters and indicate the device and software version of the body composition analyzer. In addition, the choice of body composition method should depend on the aim of the study. For assessment of changes in SM and evaluation of individual patients, a high precision is required that is, for instance, not fulfilled when segmental bioelectrical impedance is used to assess limb SM. The adverse effects of obesity on muscle quality and function may lead to an underestimation of sarcopenia in obesity and therefore requires normalization of SM for FM.

Author Contributions: Conceptualization, A.B.-W. and W.B.; methodology, C.O.W., A.B.-W. and W.B.; formal analysis, C.O.W., B.J. and W.B.; data curation (Table 5), B.J., S.P. and W.B.; writing—original draft preparation, A.B.-W., C.O.W. and W.B.; writing—review and editing, B.J., M.J.M. (Michael J. Maisch), M.J.M. (Manfred J. Müller), K.N. and S.P. All authors have read and agreed to the published version of the manuscript.

Funding: We acknowledge financial support by Land Schleswig-Holstein within the funding programme Open Access Publikationsfonds.

Conflicts of Interest: Michael Maisch and Björn Jensen are employed by seca gmbh & co. kg., Anja Bösy-Westphal serves a consultant for seca gmbh & co. kg. The other authors declare no conflict of interest.

Abbreviation

| | |
|------|--|
| ALM | appendicular lean mass |
| ASM | appendicular skeletal muscle mass |
| ASMI | appendicular skeletal muscle mass index |
| BIA | bioelectrical impedance analysis |
| BMI | body mass index |
| BSA | body surface area |
| CART | classification and regression tree analysis |
| CT | computed tomography |
| DXA | dual X-ray absorptiometry |
| FFM | fat-free mass |
| FFMI | fat-free mass index |
| FM | fat mass |
| FMI | fat mass index |
| FNIH | Foundation for the National Institutes of Health |
| IOTF | International Obesity Taskforce |

| | |
|--------|--|
| L | lumbar vertebra |
| L3 | third lumbar vertebra |
| MRI | magnetic resonance imaging |
| NA | not available |
| NAKO | German National Cohort |
| NHANES | National Health and Nutrition Examination Survey |
| NIH | National Institutes of Health |
| PMA | psoas muscle area |
| PMI | psoas muscle index |
| SAT | subcutaneous adipose tissue |
| SD | standard deviation |
| SEE | standard error of estimate |
| SM | skeletal muscle mass |
| SMI | skeletal muscle mass index |
| SMA | skeletal muscle area |
| T | thoracic vertebra |
| TAMA | total abdominal muscle area |
| TMA | thigh muscle area |
| VAT | visceral adipose tissue |
| VFA | visceral fat area |
| WC | waist circumference |
| WHO | World Health Organization |

References

- Bauer, J.; Morley, J.E.; Schols, A.M.W.J.; Ferrucci, L.; Cruz-Jentoft, A.J.; Dent, E.; Baracos, V.E.; Crawford, J.A.; Doehner, W.; Heymsfield, S.B.; et al. Sarcopenia: A Time for Action. An SCWD Position Paper. *J. Cachexia Sarcopenia Muscle* **2019**, *10*, 956–961. [[CrossRef](#)] [[PubMed](#)]
- Hanai, T.; Shiraki, M.; Nishimura, K.; Ohnishi, S.; Imai, K.; Suetsugu, A.; Takai, K.; Shimizu, M.; Moriwaki, H. Sarcopenia impairs prognosis of patients with liver cirrhosis. *Nutrition* **2015**, *31*, 193–199. [[CrossRef](#)] [[PubMed](#)]
- Lin, T.-Y.; Lim, P.-S.; Hung, S.-C. Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients with CKD. *Kidney Int. Rep.* **2018**, *3*, 447–455. [[CrossRef](#)] [[PubMed](#)]
- Caan, B.J.; Cespedes Feliciano, E.M.; Prado, C.M.; Alexeeff, S.; Kroenke, C.H.; Bradshaw, P.; Quesenberry, C.P.; Weltzien, E.K.; Castillo, A.L.; Olobatuyi, T.A.; et al. Association of Muscle and Adiposity Measured by Computed Tomography with Survival in Patients with Nonmetastatic Breast Cancer. *JAMA Oncol.* **2018**, *4*, 798–804. [[CrossRef](#)] [[PubMed](#)]
- Hopkins, J.J.; Reif, R.L.; Bigam, D.L.; Baracos, V.E.; Eurich, D.T.; Sawyer, M.B. The Impact of Muscle and Adipose Tissue on Long-term Survival in Patients with Stage I to III Colorectal Cancer. *Dis. Colon Rectum* **2019**, *62*, 549–560. [[CrossRef](#)]
- Huang, B.-T.; Peng, Y.; Liu, W.; Zhang, C.; Huang, F.-Y.; Wang, P.-J.; Zuo, Z.-L.; Liao, Y.-B.; Chai, H.; Huang, K.-S.; et al. Lean mass index, body fat and survival in Chinese patients with coronary artery disease. *QJM Int. J. Med.* **2015**, *108*, 641–647. [[CrossRef](#)]
- Medina-Inojosa, J.R.; Somers, V.K.; Thomas, R.J.; Jean, N.; Jenkins, S.M.; Gomez-Ibarra, M.A.; Supervia, M.; Lopez-Jimenez, F. Association Between Adiposity and Lean Mass with Long-Term Cardiovascular Events in Patients with Coronary Artery Disease: No Paradox. *J. Am. Heart Assoc.* **2018**, *7*. [[CrossRef](#)]
- Lavie, C.J.; De Schutter, A.; Patel, D.A.; Romero-Corral, A.; Artham, S.M.; Milani, R.V. Body Composition and Survival in Stable Coronary Heart Disease: Impact of lean mass index and body fat in the “obesity paradox”. *J. Am. Coll. Cardiol.* **2012**, *60*, 1374–1380. [[CrossRef](#)]
- Toledo, D.O.; Carvalho, A.M.; Oliveira, A.M.R.R.; Tolo, J.M.; Silva, A.C.; Francisco de Mattos Farah, J.; Prado, C.M.; Silva, J.M. The use of computed tomography images as a prognostic marker in critically ill cancer patients. *Clin. Nutr. ESPEN* **2018**, *25*, 114–120. [[CrossRef](#)]

10. Kou, H.-W.; Yeh, C.-H.; Tsai, H.-I.; Hsu, C.-C.; Hsieh, Y.-C.; Chen, W.-T.; Cheng, H.-T.; Yu, M.-C.; Lee, C.-W. Sarcopenia is an effective predictor of difficult-to-wean and mortality among critically ill surgical patients. *PLoS ONE* **2019**, *14*, e0220699. [[CrossRef](#)]
11. Moisey, L.L.; Mourtzakis, M.; Cotton, B.A.; Premji, T.; Heyland, D.K.; Wade, C.E.; Bulger, E.; Kozar, R.A.; Nutrition and Rehabilitation Investigators Consortium (NUTRIC). Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. *Crit. Care* **2013**, *17*, R206. [[CrossRef](#)]
12. Jaitovich, A.; Khan, M.M.H.S.; Itty, R.; Chieng, H.C.; Dumas, C.L.; Nadendla, P.; Fantauzzi, J.P.; Yucel, R.M.; Feustel, P.J.; Judson, M.A. ICU Admission Muscle and Fat Mass, Survival, and Disability at Discharge: A Prospective Cohort Study. *Chest* **2019**, *155*, 322–330. [[CrossRef](#)]
13. Carson, B.P. The Potential Role of Contraction-Induced Myokines in the Regulation of Metabolic Function for the Prevention and Treatment of Type 2 Diabetes. *Front. Endocrinol.* **2017**, *8*, 97. [[CrossRef](#)]
14. Lee, J.H.; Jun, H.-S. Role of Myokines in Regulating Skeletal Muscle Mass and Function. *Front. Physiol.* **2019**, *10*, 42. [[CrossRef](#)]
15. Bigaard, J.; Frederiksen, K.; Tjønneland, A.; Thomsen, B.L.; Overvad, K.; Heitmann, B.L.; Sørensen, T.I.A. Body Fat and Fat-Free Mass and All-Cause Mortality. *Obes. Res.* **2004**, *12*, 1042–1049. [[CrossRef](#)]
16. Lee, D.H.; Giovannucci, E.L. Body composition and mortality in the general population: A review of epidemiologic studies. *Exp. Biol. Med.* **2018**, *243*, 1275–1285. [[CrossRef](#)]
17. Schweitzer, L.; Geisler, C.; Pourhassan, M.; Braun, W.; Glüer, C.-C.; Bosity-Westphal, A.; Müller, M.J. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? *Am. J. Clin. Nutr.* **2015**, *102*, 58–65. [[CrossRef](#)]
18. Heymsfield, S.B.; Gonzalez, M.C.; Lu, J.; Jia, G.; Zheng, J. Skeletal muscle mass and quality: Evolution of modern measurement concepts in the context of sarcopenia. *Proc. Nutr. Soc.* **2015**, *74*, 355–366. [[CrossRef](#)]
19. Jung Lee, S.; Janssen, I.; Heymsfield, S.B.; Ross, R. Relation between whole-body and regional measures of human skeletal muscle. *Am. J. Clin. Nutr.* **2004**, *80*, 1215–1221. [[CrossRef](#)]
20. Bahat, G.; Saka, B.; Tufan, F.; Akin, S.; Sivrikaya, S.; Yucel, N.; Erten, N.; Karan, M.A. Prevalence of sarcopenia and its association with functional and nutritional status among male residents in a nursing home in Turkey. *Aging Male* **2010**, *13*, 211–214. [[CrossRef](#)]
21. Krzywińska-Siemaszko, R.; Fryzowicz, A.; Czepulis, N.; Kaluźniak-Szymanowska, A.; Dworak, L.B.; Wiczorowska-Tobis, K. The impact of the age range of young healthy reference population on the cut-off points for low muscle mass necessary for the diagnosis of sarcopenia. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 4321–4332. [[CrossRef](#)]
22. Alkahtani, S.A. A cross-sectional study on sarcopenia using different methods: Reference values for healthy Saudi young men. *BMC Musculoskelet. Disord.* **2017**, *18*, 119. [[CrossRef](#)]
23. Yamada, M.; Nishiguchi, S.; Fukutani, N.; Tanigawa, T.; Yukutake, T.; Kayama, H.; Aoyama, T.; Arai, H. Prevalence of Sarcopenia in Community-Dwelling Japanese Older Adults. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 911–915. [[CrossRef](#)]
24. Janssen, I.; Baumgartner, R.N.; Ross, R.; Rosenberg, I.H.; Roubenoff, R. Skeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women. *Am. J. Epidemiol.* **2004**, *159*, 413–421. [[CrossRef](#)]
25. Tichet, J.; Vol, S.; Goxe, D.; Salle, A.; Berrut, G.; Ritz, P. Prevalence of sarcopenia in the French senior population. *J. Nutr. Health Aging* **2008**, *12*, 202–206. [[CrossRef](#)]
26. Masanés, F.; Culla, A.; Navarro-Gonzalez, M.; Navarro-Lopez, M.; Sacanella, E.; Torres, B.; Lopez-Soto, A. Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of Barcelona (Spain). *J. Nutr. Health Aging* **2012**, *16*, 184–187. [[CrossRef](#)]
27. Bosity-Westphal, A.; Jensen, B.; Braun, W.; Pourhassan, M.; Gallagher, D.; Müller, M.J. Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. *Eur. J. Clin. Nutr.* **2017**, *71*, 1061–1067. [[CrossRef](#)]
28. Prado, C.M.; Siervo, M.; Mire, E.; Heymsfield, S.B.; Stephan, B.C.; Broyles, S.; Smith, S.R.; Wells, J.C.; Katzmarzyk, P.T. A population-based approach to define body-composition phenotypes. *Am. J. Clin. Nutr.* **2014**, *99*, 1369–1377. [[CrossRef](#)]
29. Akhmedov, D.; Berdeaux, R. The effects of obesity on skeletal muscle regeneration. *Front. Physiol.* **2013**, *4*. [[CrossRef](#)]

30. Wu, H.; Ballantyne, C.M. Skeletal muscle inflammation and insulin resistance in obesity. *J. Clin. Invest.* **2017**, *127*, 43–54. [[CrossRef](#)]
31. Cederholm, T.; Jensen, G.L.; Correia, M.I.T.D.; Gonzalez, M.C.; Fukushima, R.; Higashiguchi, T.; Baptista, G.; Barazzoni, R.; Blaauw, R.; Coats, A.; et al. GLIM criteria for the diagnosis of malnutrition—A consensus report from the global clinical nutrition community. *Clin. Nutr.* **2019**, *38*, 1–9. [[CrossRef](#)] [[PubMed](#)]
32. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.-P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **2010**, *39*, 412–423. [[CrossRef](#)]
33. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **2019**, *48*, 16–31. [[CrossRef](#)] [[PubMed](#)]
34. Chen, L.-K.; Liu, L.-K.; Woo, J.; Assantachai, P.; Auyeung, T.-W.; Bahyah, K.S.; Chou, M.-Y.; Chen, L.-Y.; Hsu, P.-S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 95–101. [[CrossRef](#)]
35. Chen, L.-K.; Lee, W.-J.; Peng, L.-N.; Liu, L.-K.; Arai, H.; Akishita, M. Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 767.e1–767.e7. [[CrossRef](#)]
36. Studenski, S.A.; Peters, K.W.; Alley, D.E.; Cawthon, P.M.; McLean, R.R.; Harris, T.B.; Ferrucci, L.; Guralnik, J.M.; Fragala, M.S.; Kenny, A.M.; et al. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. *J. Gerontol. A Biomed. Sci. Med. Sci.* **2014**, *69*, 547–558. [[CrossRef](#)] [[PubMed](#)]
37. Fielding, R.A.; Vellas, B.; Evans, W.J.; Bhasin, S.; Morley, J.E.; Newman, A.B.; Abellan van Kan, G.; Andrieu, S.; Bauer, J.; Breuille, D.; et al. Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. *J. Am. Med. Dir. Assoc.* **2011**, *12*, 249–256. [[CrossRef](#)] [[PubMed](#)]
38. Imboden, M.T.; Swartz, A.M.; Finch, H.W.; Harber, M.P.; Kaminsky, L.A. Reference standards for lean mass measures using GE dual energy x-ray absorptiometry in Caucasian adults. *PLoS ONE* **2017**, *12*, e0176161. [[CrossRef](#)]
39. Kruger, H.S.; Micklesfield, L.K.; Wright, H.H.; Havemann-Nel, L.; Goedecke, J.H. Ethnic-specific cut-points for sarcopenia: Evidence from black South African women. *Eur. J. Clin. Nutr.* **2015**, *69*, 843–849. [[CrossRef](#)]
40. Alemán-Mateo, H.; Ruiz Valenzuela, R.E. Skeletal Muscle Mass Indices in Healthy Young Mexican Adults Aged 20–40 Years: Implications for Diagnoses of Sarcopenia in the Elderly Population. *Sci. World J.* **2014**, *2014*. [[CrossRef](#)]
41. Gould, H.; Brennan, S.L.; Kotowicz, M.A.; Nicholson, G.C.; Pasco, J.A. Total and Appendicular Lean Mass Reference Ranges for Australian Men and Women: The Geelong Osteoporosis Study. *Calcif. Tissue Int.* **2014**, *94*, 363–372. [[CrossRef](#)] [[PubMed](#)]
42. Marwaha, R.K.; Garg, M.K.; Bhadra, K.; Mithal, A.; Tandon, N. Assessment of lean (muscle) mass and its distribution by dual energy X-ray absorptiometry in healthy Indian females. *Arch. Osteoporos.* **2014**, *9*, 186. [[CrossRef](#)] [[PubMed](#)]
43. Yu, R.; Wong, M.; Leung, J.; Lee, J.; Auyeung, T.W.; Woo, J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults: Sarcopenia incidence and its risk factors. *Geriatr. Gerontol. Int.* **2014**, *14*, 15–28. [[CrossRef](#)] [[PubMed](#)]
44. Kim, Y.-S.; Lee, Y.; Chung, Y.-S.; Lee, D.-J.; Joo, N.-S.; Hong, D.; Song, G.; Kim, H.-J.; Choi, Y.J.; Kim, K.-M. Prevalence of Sarcopenia and Sarcopenic Obesity in the Korean Population Based on the Fourth Korean National Health and Nutritional Examination Surveys. *J. Gerontol. A Biomed. Sci. Med. Sci.* **2012**, *67*, 1107–1113. [[CrossRef](#)]
45. Oliveira, R.J.; Bottaro, M.; Júnior, J.T.; Farinatti, P.T.V.; Bezerra, L.A.; Lima, R.M. Identification of sarcopenic obesity in postmenopausal women: A cutoff proposal. *Braz. J. Med. Biol. Res.* **2011**, *44*, 1171–1176. [[CrossRef](#)]
46. Sanada, K.; Miyachi, M.; Tanimoto, M.; Yamamoto, K.; Murakami, H.; Okumura, S.; Gando, Y.; Suzuki, K.; Tabata, I.; Higuchi, M. A cross-sectional study of sarcopenia in Japanese men and women: Reference values and association with cardiovascular risk factors. *Eur. J. Appl. Physiol.* **2010**, *110*, 57–65. [[CrossRef](#)]
47. Szulc, P.; Duboeuf, F.; Marchand, F.; Delmas, P.D. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: The MINOS study. *Am. J. Clin. Nutr.* **2004**, *80*, 496–503. [[CrossRef](#)]

48. Newman, A.B.; Kupelian, V.; Visser, M.; Simonsick, E.; Goodpaster, B.; Nevitt, M.; Kritchevsky, S.B.; Tylavsky, F.A.; Rubin, S.M.; Harris, T.B.; et al. Sarcopenia: Alternative Definitions and Associations with Lower Extremity Function. *J. Am. Geriatr. Soc.* **2003**, *51*, 1602–1609. [[CrossRef](#)]
49. Tankó, L.B.; Movsesyan, L.; Mouritzen, U.; Christiansen, C.; Svendsen, O.L. Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. *Metabolism* **2002**, *51*, 69–74. [[CrossRef](#)]
50. Baumgartner, R.N.; Koehler, K.M.; Gallagher, D.; Romero, L.; Heymsfield, S.B.; Ross, R.R.; Garry, P.J.; Lindeman, R.D. Epidemiology of Sarcopenia among the Elderly in New Mexico. *Am. J. Epidemiol.* **1998**, *147*, 755–763. [[CrossRef](#)]
51. Kim, J.; Wang, Z.; Heymsfield, S.B.; Baumgartner, R.N.; Gallagher, D. Total-body skeletal muscle mass: Estimation by a new dual-energy X-ray absorptiometry method. *Am. Clin. Nutr.* **2002**, *76*, 378–383. [[CrossRef](#)] [[PubMed](#)]
52. Bahat, G.; Tufan, A.; Tufan, F.; Kilic, C.; Akpınar, T.S.; Kose, M.; Erten, N.; Karan, M.A.; Cruz-Jentoft, A.J. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. *Clin. Nutr.* **2016**, *35*, 1557–1563. [[CrossRef](#)] [[PubMed](#)]
53. Chang, C.-I.; Chen, C.-Y.; Huang, K.-C.; Wu, C.-H.; Hsiung, C.A.; Hsu, C.-C.; Chen, C.-Y. Comparison of three BIA muscle indices for sarcopenia screening in old adults. *Eur. Geriatr. Med.* **2013**, *4*, 145–149. [[CrossRef](#)]
54. Tanimoto, Y.; Watanabe, M.; Sun, W.; Sugiura, Y.; Tsuda, Y.; Kimura, M.; Hayashida, I.; Kusabiraki, T.; Kono, K. Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan. *Arch. Gerontol. Geriatr.* **2012**, *55*, e9–e13. [[CrossRef](#)]
55. Chien, M.-Y.; Huang, T.-Y.; Wu, Y.-T. Prevalence of Sarcopenia Estimated Using a Bioelectrical Impedance Analysis Prediction Equation in Community-Dwelling Elderly People in Taiwan. *J. Am. Geriatr. Soc.* **2008**, *56*, 1710–1715. [[CrossRef](#)]
56. Janssen, I.; Heymsfield, S.B.; Baumgartner, R.N.; Ross, R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. *J. Appl. Physiol.* **2000**, *89*, 465–471. [[CrossRef](#)]
57. Ufuk, F.; Herek, D. Reference Skeletal Muscle Mass Values at L3 Vertebrae Level Based on Computed Tomography in Healthy Turkish Adults. *Int. J. Geront.* **2019**, *13*, 221–225.
58. Derstine, B.A.; Holcombe, S.A.; Ross, B.E.; Wang, N.C.; Su, G.L.; Wang, S.C. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. *Sci. Rep.* **2018**, *8*, 11369. [[CrossRef](#)]
59. van der Werf, A.; Langius, J.A.E.; de van der Schueren, M.A.E.; Nurmohamed, S.A.; van der Pant, K.A.M.I.; Blauwhoff-Busker, S.; Wierdsma, N.J. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. *Eur. J. Clin. Nutr.* **2018**, *72*, 288–296. [[CrossRef](#)]
60. Benjamin, J.; Shashtry, V.; Kaal, C.R.; Anand, L.; Bhardwaj, A.; Pandit, V.; Arora, A.; Rajesh, S.; Pamecha, V.; Jain, V.; et al. Characterization of body composition and definition of sarcopenia in patients with alcoholic cirrhosis: A computed tomography based study. *Liver Int.* **2017**, *37*, 1668–1674. [[CrossRef](#)]
61. Kim, J.S.; Kim, W.Y.; Park, H.K.; Kim, M.C.; Jung, W.; Ko, B.S. Simple Age Specific Cutoff Value for Sarcopenia Evaluated by Computed Tomography. *Ann. Nutr. Metab.* **2017**, *71*, 157–163. [[CrossRef](#)] [[PubMed](#)]
62. Sakurai, K.; Kubo, N.; Tamura, T.; Toyokawa, T.; Amano, R.; Tanaka, H.; Muguruma, K.; Yashiro, M.; Maeda, K.; Hirakawa, K.; et al. Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer. *Ann. Surg. Oncol.* **2017**, *24*, 2712–2719. [[CrossRef](#)] [[PubMed](#)]
63. Hamaguchi, Y.; Kaido, T.; Okumura, S.; Kobayashi, A.; Hammad, A.; Tamai, Y.; Inagaki, N.; Uemoto, S. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. *Nutrition* **2016**, *32*, 1200–1205. [[CrossRef](#)] [[PubMed](#)]
64. Zhuang, C.-L.; Huang, D.-D.; Pang, W.-Y.; Zhou, C.-J.; Wang, S.-L.; Lou, N.; Ma, L.-L.; Yu, Z.; Shen, X. Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort. *Medicine* **2016**, *95*, e3164. [[CrossRef](#)] [[PubMed](#)]
65. Iritani, S.; Imai, K.; Takai, K.; Hanai, T.; Ideta, T.; Miyazaki, T.; Suetsugu, A.; Shiraki, M.; Shimizu, M.; Moriwaki, H. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. *J. Gastroenterol.* **2015**, *50*, 323–332. [[CrossRef](#)]

66. Chiles Shaffer, N.; Ferrucci, L.; Shardell, M.; Simonsick, E.M.; Studenski, S. Agreement and Predictive Validity Using Less-Conservative Foundation for the National Institutes of Health Sarcopenia Project Weakness Cutpoints. *J. Am. Geriatr. Soc.* **2017**, *65*, 574–579. [[CrossRef](#)]
67. Cawthon, P.M.; Peters, K.W.; Shardell, M.D.; McLean, R.R.; Dam, T.-T.L.; Kenny, A.M.; Fragala, M.S.; Harris, T.B.; Kiel, D.P.; Guralnik, J.M.; et al. Cutpoints for Low Appendicular Lean Mass That Identify Older Adults with Clinically Significant Weakness. *J. Gerontol. A Biomed. Sci. Med. Sci.* **2014**, *69*, 567–575. [[CrossRef](#)]
68. Biolo, G.; Di Girolamo, F.G.; Breglia, A.; Chiuc, M.; Baglio, V.; Vinci, P.; Toigo, G.; Lucchin, L.; Jurdana, M.; Pražnikar, Z.J.; et al. Inverse relationship between “a body shape index” (ABSI) and fat-free mass in women and men: Insights into mechanisms of sarcopenic obesity. *Clin. Nutr.* **2015**, *34*, 323–327. [[CrossRef](#)]
69. Lim, K.I.; Yang, S.J.; Kim, T.N.; Yoo, H.J.; Kang, H.J.; Song, W.; Baik, S.H.; Choi, D.S.; Choi, K.M. The association between the ratio of visceral fat to thigh muscle area and metabolic syndrome: The Korean Sarcopenic Obesity Study (KSOS). *Clin. Endocrinol.* **2010**, *73*, 588–594. [[CrossRef](#)]
70. Atkins, J.L.; Whincup, P.H.; Morris, R.W.; Lennon, L.T.; Papacosta, O.; Wannamethee, S.G. Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Population-Based Cohort Study of Older Men. *J. Am. Geriatr. Soc.* **2014**, *62*, 253–260. [[CrossRef](#)]
71. Prado, C.M.; Lieffers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. *Lancet Oncol.* **2008**, *9*, 629–635. [[CrossRef](#)]
72. Martin, L.; Birdsell, L.; MacDonald, N.; Reiman, T.; Clandinin, M.T.; McCargar, L.J.; Murphy, R.; Ghosh, S.; Sawyer, M.B.; Baracos, V.E. Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. *J. Clin. Oncol.* **2013**, *31*, 1539–1547. [[CrossRef](#)] [[PubMed](#)]
73. Nishigori, T.; Tsunoda, S.; Okabe, H.; Tanaka, E.; Hisamori, S.; Hosogi, H.; Shinohara, H.; Sakai, Y. Impact of Sarcopenic Obesity on Surgical Site Infection after Laparoscopic Total Gastrectomy. *Ann. Surg. Oncol.* **2016**, *23*, 524–531. [[CrossRef](#)] [[PubMed](#)]
74. Pecorelli, N.; Carrara, G.; De Cobelli, F.; Cristel, G.; Damascelli, A.; Balzano, G.; Beretta, L.; Braga, M. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. *Br. J. Surg.* **2016**, *103*, 434–442. [[CrossRef](#)]
75. Cushen, S.J.; Power, D.G.; Murphy, K.P.; McDermott, R.; Griffin, B.T.; Lim, M.; Daly, L.; MacEneaney, P.; O’ Sullivan, K.; Prado, C.M.; et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. *Clin. Nutr. ESPEN* **2016**, *13*, e39–e45. [[CrossRef](#)] [[PubMed](#)]
76. Muscariello, E.; Nasti, G.; Siervo, M.; Di Maro, M.; Lapi, D.; D’Addio, G.; Colantuoni, A. Dietary protein intake in sarcopenic obese older women. *Clin. Interv. Aging* **2016**, *133*. [[CrossRef](#)]
77. Antoun, S.; Baracos, V.E.; Birdsell, L.; Escudier, B.; Sawyer, M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. *Ann. Oncol.* **2010**, *21*, 1594–1598. [[CrossRef](#)]
78. Barret, M.; Antoun, S.; Dalban, C.; Malka, D.; Mansoubakht, T.; Zaanani, A.; Latko, E.; Taieb, J. Sarcopenia Is Linked to Treatment Toxicity in Patients with Metastatic Colorectal Cancer. *Nutr. Cancer* **2014**, *66*, 583–589. [[CrossRef](#)]
79. Huillard, O.; Mir, O.; Peyromaure, M.; Tlemsani, C.; Giroux, J.; Boudou-Rouquette, P.; Ropert, S.; Delongchamps, N.B.; Zerbib, M.; Goldwasser, F. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. *Br. J. Cancer* **2013**, *108*, 1034–1041. [[CrossRef](#)]
80. De Rosa, E.; Santarpia, L.; Marra, M.; Sammarco, R.; Amato, V.; Onufrio, M.; De Simone, G.; Contaldo, F.; Pasanisi, F. Preliminary evaluation of the prevalence of sarcopenia in obese patients from Southern Italy. *Nutrition* **2015**, *31*, 79–83. [[CrossRef](#)]
81. Kemmler, W.; von Stengel, S.; Engelke, K.; Sieber, C.; Freiburger, E. Prevalence of sarcopenic obesity in Germany using established definitions: Baseline data of the FORMOsA study. *Osteoporos. Int.* **2016**, *27*, 275–281. [[CrossRef](#)] [[PubMed](#)]
82. Kim, M.K.; Baek, K.H.; Song, K.-H.; Il Kang, M.; Park, C.Y.; Lee, W.Y.; Oh, K.W. Vitamin D Deficiency Is Associated with Sarcopenia in Older Koreans, Regardless of Obesity: The Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. *J. Clin. Endocrinol. Metab.* **2011**, *96*, 3250–3256. [[CrossRef](#)]

83. Lee, S.; Kim, T.-N.; Kim, S.-H. Sarcopenic obesity is more closely associated with knee osteoarthritis than is nonsarcopenic obesity: A cross-sectional study. *Arthritis Rheum.* **2012**, *64*, 3947–3954. [[CrossRef](#)] [[PubMed](#)]
84. Ramachandran, R.; Gravenstein, K.S.; Metter, E.J.; Egan, J.M.; Ferrucci, L.; Chia, C.W. Selective Contribution of Regional Adiposity, Skeletal Muscle, and Adipokines to Glucose Disposal in Older Adults. *J. Am. Geriatr. Soc.* **2012**, *60*, 707–712. [[CrossRef](#)] [[PubMed](#)]
85. Kwon, S.S.; Lee, S.-G.; Lee, Y.; Lim, J.-B.; Kim, J.-H. Homeostasis model assessment of insulin resistance in a general adult population in Korea: Additive association of sarcopenia and obesity with insulin resistance. *Clin. Endocrinol.* **2017**, *86*, 44–51. [[CrossRef](#)]
86. Lee, Y.; Jung, K.S.; Kim, S.U.; Yoon, H.; Yun, Y.J.; Lee, B.-W.; Kang, E.S.; Han, K.-H.; Lee, H.C.; Cha, B.-S. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). *J. Hepatol.* **2015**, *63*, 486–493. [[CrossRef](#)]
87. Oh, C.; Jho, S.; No, J.-K.; Kim, H.-S. Body composition changes were related to nutrient intakes in elderly men but elderly women had a higher prevalence of sarcopenic obesity in a population of Korean adults. *Nutr. Res.* **2015**, *35*, 1–6. [[CrossRef](#)]
88. Chung, J.-Y.; Kang, H.-T.; Lee, D.-C.; Lee, H.-R.; Lee, Y.-J. Body composition and its association with cardiometabolic risk factors in the elderly: A focus on sarcopenic obesity. *Arch. Gerontol. Geriatr.* **2013**, *56*, 270–278. [[CrossRef](#)]
89. Baek, J.; Park, D.; Kim, I.; Won, J.-U.; Hwang, J.; Roh, J. Autonomic dysfunction of overweight combined with low muscle mass. *Clin. Auton. Res.* **2013**, *23*, 325–331. [[CrossRef](#)]
90. Baek, S.J.; Nam, G.E.; Han, K.D.; Choi, S.W.; Jung, S.W.; Bok, A.R.; Kim, Y.H.; Lee, K.S.; Han, B.D.; Kim, D.H. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: The 2008–2010 Korea National Health and Nutrition Examination Survey. *J. Endocrinol. Investig.* **2014**, *37*, 247–260. [[CrossRef](#)]
91. Lou, N.; Chi, C.-H.; Chen, X.-D.; Zhou, C.-J.; Wang, S.-L.; Zhuang, C.-L.; Shen, X. Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: A prospective study. *Eur. J. Surg. Oncol.* **2017**, *43*, 188–195. [[CrossRef](#)] [[PubMed](#)]
92. Moreira, M.A.; Zunzunegui, M.V.; Vafaei, A.; da Câmara, S.M.A.; Oliveira, T.S.; Maciel, Á.C.C. Sarcopenic obesity and physical performance in middle aged women: A cross-sectional study in Northeast Brazil. *BMC Public Health* **2016**, *16*, 43. [[CrossRef](#)] [[PubMed](#)]
93. Hwang, B.; Lim, J.-Y.; Lee, J.; Choi, N.-K.; Ahn, Y.-O.; Park, B.-J. Prevalence Rate and Associated Factors of Sarcopenic Obesity in Korean Elderly Population. *J. Korean Med. Sci.* **2012**, *27*, 748–755. [[CrossRef](#)] [[PubMed](#)]
94. Cho, Y.; Shin, S.-Y.; Shin, M.-J. Sarcopenic obesity is associated with lower indicators of psychological health and quality of life in Koreans. *Nutr. Res.* **2015**, *35*, 384–392. [[CrossRef](#)] [[PubMed](#)]
95. An, K.O.; Kim, J. Association of Sarcopenia and Obesity with Multimorbidity in Korean Adults: A Nationwide Cross-Sectional Study. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 960.e1–960.e7. [[CrossRef](#)]
96. Bahat, G.; Kilic, C.; Topcu, Y.; Aydin, K.; Karan, M.A. Fat percentage cutoff values to define obesity and prevalence of sarcopenic obesity in community-dwelling older adults in Turkey. *Aging Male* **2018**, 1–7. [[CrossRef](#)]
97. Ishii, S.; Chang, C.; Tanaka, T.; Kuroda, A.; Tsuji, T.; Akishita, M.; Iijima, K. The Association between Sarcopenic Obesity and Depressive Symptoms in Older Japanese Adults. *PLoS ONE* **2016**, *11*, e0162898. [[CrossRef](#)]
98. Kim, T.N.; Yang, S.J.; Yoo, H.J.; Lim, K.I.; Kang, H.J.; Song, W.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean sarcopenic obesity study. *Int. J. Obes.* **2009**, *33*, 885–892. [[CrossRef](#)]
99. Lee, J.; Hong, Y.; Shin, H.J.; Lee, W. Associations of Sarcopenia and Sarcopenic Obesity with Metabolic Syndrome Considering Both Muscle Mass and Muscle Strength. *J. Prev. Med. Public Health* **2016**, *49*, 35–44. [[CrossRef](#)]
100. Gomez-Cabello, A.; Pedrero-Chamizo, R.; Olivares, P.R.; Luzardo, L.; Juez-Bengochea, A.; Mata, E.; Albers, U.; Aznar, S.; Villa, G.; Espino, L.; et al. Prevalence of overweight and obesity in non-institutionalized people aged 65 or over from Spain: The elderly EXERNET multi-centre study: Adiposity and lifestyle in Spanish elderly. *Obes. Rev.* **2011**, *12*, 583–592. [[CrossRef](#)]

101. Rolland, Y.; Lauwers-Cances, V.; Cristini, C.; van Kan, G.A.; Janssen, I.; Morley, J.E.; Vellas, B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l'OSteoporose) Study. *Am. J. Clin. Nutr.* **2009**, *89*, 1895–1900. [[CrossRef](#)] [[PubMed](#)]
102. Kelly, T.L.; Wilson, K.E.; Heymsfield, S.B. Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANES. *PLoS ONE* **2009**, *4*, e7038. [[CrossRef](#)] [[PubMed](#)]
103. Snyder, W.S.C.; Cook, M.J.; Nasset, E.S.; Karhansen, L.R.; Howells, G.P.; Tipton, I.H. *Report of the Task Group on Reference Men*; Pergamon Press: Oxford, UK, 1975.
104. Schautz, B.; Later, W.; Heller, M.; Müller, M.J.; Böszy-Westphal, A. Total and regional relationship between lean and fat mass with increasing adiposity—Impact for the diagnosis of sarcopenic obesity. *Eur. J. Clin. Nutr.* **2012**, *66*, 1356–1361. [[CrossRef](#)] [[PubMed](#)]
105. Linge, J.; Borga, M.; West, J.; Tuthill, T.; Miller, M.R.; Dumitriu, A.; Thomas, E.L.; Romu, T.; Tunón, P.; Bell, J.D.; et al. Body Composition Profiling in the UK Biobank Imaging Study. *Obesity* **2018**, *26*, 1785–1795. [[CrossRef](#)] [[PubMed](#)]
106. Bamberg, F.; Kauczor, H.-U.; Weckbach, S.; Schlett, C.L.; Forsting, M.; Ladd, S.C.; Greiser, K.H.; Weber, M.-A.; Schulz-Menger, J.; Niendorf, T.; et al. Whole-Body MR Imaging in the German National Cohort: Rationale, Design, and Technical Background. *Radiology* **2015**, *277*, 206–220. [[CrossRef](#)] [[PubMed](#)]
107. MacDonald, A.J.; Greig, C.A.; Baracos, V. The advantages and limitations of cross-sectional body composition analysis. *Curr. Opin. Support. Palliat. Care* **2011**, *5*, 342–349. [[CrossRef](#)] [[PubMed](#)]
108. Prado, C.M.M.; Heymsfield, S.B. Lean Tissue Imaging: A New Era for Nutritional Assessment and Intervention. *J. Parenter. Enter. Nutr.* **2014**, *38*, 940–953. [[CrossRef](#)]
109. Visser, M.; Fuerst, T.; Lang, T.; Salamone, L.; Harris, T.B. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study—Dual-Energy X-ray Absorptiometry and Body Composition Working Group. *J. Appl. Physiol.* **1999**, *87*, 1513–1520. [[CrossRef](#)]
110. Hansen, R.D.; Williamson, D.A.; Finnegan, T.P.; Lloyd, B.D.; Grady, J.N.; Diamond, T.H.; Smith, E.U.; Stavrinou, T.M.; Thompson, M.W.; Gwinn, T.H.; et al. Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients. *Am. J. Clin. Nutr.* **2007**, *86*, 952–958. [[CrossRef](#)]
111. Zhao, X.; Wang, Z.; Zhang, J.; Hua, J.; He, W.; Zhu, S. Estimation of Total Body Skeletal Muscle Mass in Chinese Adults: Prediction Model by Dual-Energy X-Ray Absorptiometry. *PLoS ONE* **2013**, *8*, e53561. [[CrossRef](#)]
112. Freda, P.U.; Shen, W.; Reyes-Vidal, C.M.; Geer, E.B.; Arias-Mendoza, F.; Gallagher, D.; Heymsfield, S.B. Skeletal Muscle Mass in Acromegaly Assessed by Magnetic Resonance Imaging and Dual-Photon X-Ray Absorptiometry. *J. Clin. Endocrinol. Metab.* **2009**, *94*, 2880–2886. [[CrossRef](#)] [[PubMed](#)]
113. Bridge, P.; Pocock, N.A.; Nguyen, T.; Munns, C.; Cowell, C.T.; Forwood, N.; Thompson, M.W. Validation of Longitudinal DXA Changes in Body Composition From Pre- to Mid-Adolescence Using MRI as Reference. *J. Clin. Densitom.* **2011**, *14*, 340–347. [[CrossRef](#)] [[PubMed](#)]
114. Bredella, M.A.; Ghomi, R.H.; Thomas, B.J.; Torriani, M.; Brick, D.J.; Gerweck, A.V.; Misra, M.; Klibanski, A.; Miller, K.K. Comparison of DXA and CT in the Assessment of Body Composition in Premenopausal Women with Obesity and Anorexia Nervosa. *Obesity* **2010**, *18*, 2227–2233. [[CrossRef](#)] [[PubMed](#)]
115. Bilsborough, J.C.; Greenway, K.; Opar, D.; Livingstone, S.; Cordy, J.; Coutts, A.J. The accuracy and precision of DXA for assessing body composition in team sport athletes. *J. Sports Sci.* **2014**, *32*, 1821–1828. [[CrossRef](#)] [[PubMed](#)]
116. Jensen, B.; Braun, W.; Geisler, C.; Both, M.; Klückmann, K.; Müller, M.J.; Böszy-Westphal, A. Limitations of Fat-Free Mass for the Assessment of Muscle Mass in Obesity. *Obes. Facts* **2019**, *12*, 307–315. [[CrossRef](#)] [[PubMed](#)]
117. Buckinx, F.; Landi, F.; Cesari, M.; Fielding, R.A.; Visser, M.; Engelke, K.; Maggi, S.; Dennison, E.; Al-Daghri, N.M.; Allepaerts, S.; et al. Pitfalls in the measurement of muscle mass: A need for a reference standard. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 269–278. [[CrossRef](#)]
118. Böszy-Westphal, A.; Schautz, B.; Later, W.; Kehayias, J.J.; Gallagher, D.; Müller, M.J. What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. *Eur. J. Clin. Nutr.* **2013**, *67*, S14–S21. [[CrossRef](#)]

119. Dehghan, M.; Merchant, A.T. Is bioelectrical impedance accurate for use in large epidemiological studies? *Nutr. J.* **2008**, *7*, 26. [[CrossRef](#)]
120. Mourtzakis, M.; Prado, C.M.M.; Lieffers, J.R.; Reiman, T.; McCargar, L.J.; Baracos, V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Appl. Physiol. Nutr. Metab.* **2008**, *33*, 997–1006. [[CrossRef](#)]
121. Shen, W.; Punyanitya, M.; Wang, Z.; Gallagher, D.; St-Onge, M.-P.; Albu, J.; Heymsfield, S.B.; Heshka, S. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. *J. Appl. Physiol.* **2004**, *97*, 2333–2338. [[CrossRef](#)]
122. Rutten, I.J.G.; Ubachs, J.; Kruitwagen, R.F.P.M.; Beets-Tan, R.G.H.; Olde Damink, S.W.M.; Van Gorp, T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 630–638. [[CrossRef](#)]
123. Baracos, V.E. Psoas as a sentinel muscle for sarcopenia: A flawed premise. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 527–528. [[CrossRef](#)]
124. Müller, M.J.; Braun, W.; Enderle, J.; Bosy-Westphal, A. Beyond BMI: Conceptual Issues Related to Overweight and Obese Patients. *Obes. Facts* **2016**, *9*, 193–205. [[CrossRef](#)]
125. Maden-Wilkinson, T.M.; Degens, H.; Jones, D.A.; McPhee, J.S. Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. *J. Musculoskelet. Neuronal Interact.* **2013**, *13*, 320–328.
126. Tavoian, D.; Ampomah, K.; Amano, S.; Law, T.D.; Clark, B.C. Changes in DXA-derived lean mass and MRI-derived cross-sectional area of the thigh are modestly associated. *Sci. Rep.* **2019**, *9*, 10028. [[CrossRef](#)]
127. Bosy-Westphal, A.; Müller, M.J. Identification of skeletal muscle mass depletion across age and BMI groups in health and disease—There is need for a unified definition. *Int. J. Obes.* **2015**, *39*, 379–386. [[CrossRef](#)]
128. Heymsfield, S.B.; Heo, M.; Thomas, D.; Pietrobelli, A. Scaling of body composition to height: Relevance to height-normalized indexes. *Am. J. Clin. Nutr.* **2011**, *93*, 736–740. [[CrossRef](#)]
129. Forbes, G.B. Lean Body Mass-Body Fat Interrelationships in Humans. *Nutr. Rev.* **2009**, *45*, 225–231. [[CrossRef](#)]
130. Hulens, M.; Vansant, G.; Claessens, A.L.; Lysens, R.; Muls, E. Predictors of 6-min walk test results in lean, obese and morbidly obese women. *Scand. J. Med. Sci. Sports* **2003**, *13*, 98–105. [[CrossRef](#)]
131. Baracos, V.E.; Arribas, L. Sarcopenic obesity: Hidden muscle wasting and its impact for survival and complications of cancer therapy. *Ann. Oncol.* **2018**, *29*, ii1–ii9. [[CrossRef](#)]
132. Hattori, K.; Tatsumi, N.; Tanaka, S. Assessment of body composition by using a new chart method. *Am. J. Hum. Biol.* **1997**, *9*, 573–578. [[CrossRef](#)]
133. Schutz, Y.; Kyle, U.; Pichard, C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18–98 y. *Int. J. Obes. Relat. Metab. Disord.* **2002**, *26*, 953–960. [[CrossRef](#)]
134. Feliciano, E.M.C.; Kroenke, C.H.; Meyerhardt, J.A.; Prado, C.M.; Bradshaw, P.T.; Kwan, M.L.; Xiao, J.; Alexeeff, S.; Corley, D.; Weltzien, E.; et al. Association of Systemic Inflammation and Sarcopenia with Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. *JAMA Oncol.* **2017**, *3*, e172319. [[CrossRef](#)] [[PubMed](#)]
135. Wells, J.C.K.; Vitora, C.G. Indices of whole-body and central adiposity for evaluating the metabolic load of obesity. *Int. J. Obes.* **2005**, *29*, 483–489. [[CrossRef](#)]
136. Coin, A.; Sarti, S.; Ruggiero, E.; Giannini, S.; Pedrazzoni, M.; Minisola, S.; Rossini, M.; Del Puente, A.; Inelmen, E.M.; Manzano, E.; et al. Prevalence of Sarcopenia Based on Different Diagnostic Criteria Using DEXA and Appendicular Skeletal Muscle Mass Reference Values in an Italian Population Aged 20 to 80. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 507–512. [[CrossRef](#)]
137. Lee, W.-J.; Liu, L.-K.; Peng, L.-N.; Lin, M.-H.; Chen, L.-K. Comparisons of Sarcopenia Defined by IWGS and EWGSOP Criteria Among Older People: Results From the I-Lan Longitudinal Aging Study. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 528.e1–528.e7. [[CrossRef](#)]
138. Han, P.; Kang, L.; Guo, Q.; Wang, J.; Zhang, W.; Shen, S.; Wang, X.; Dong, R.; Ma, Y.; Shi, Y.; et al. Prevalence and Factors Associated with Sarcopenia in Suburb-dwelling Older Chinese Using the Asian Working Group for Sarcopenia Definition. *J. Gerontol. A Biomed. Sci. Med. Sci.* **2016**, *71*, 529–535. [[CrossRef](#)]
139. Yuki, A.; Ando, F.; Otsuka, R.; Matsui, Y.; Harada, A.; Shimokata, H. Epidemiology of sarcopenia in elderly Japanese. *J. Phys. Fit. Sports Med.* **2015**, *4*, 111–115. [[CrossRef](#)]
140. Ishii, S.; Tanaka, T.; Shibasaki, K.; Ouchi, Y.; Kikutani, T.; Higashiguchi, T.; Obuchi, S.P.; Ishikawa-Takata, K.; Hirano, H.; Kawai, H.; et al. Development of a simple screening test for sarcopenia in older adults. *Geriatr. Gerontol. Int.* **2014**, *14*, 93–101. [[CrossRef](#)]

141. Cheng, Q.; Zhu, X.; Zhang, X.; Li, H.; Du, Y.; Hong, W.; Xue, S.; Zhu, H. A cross-sectional study of loss of muscle mass corresponding to sarcopenia in healthy Chinese men and women: Reference values, prevalence, and association with bone mass. *J. Bone Miner. Metab.* **2014**, *32*, 78–88. [[CrossRef](#)]
142. Janssen, I.; Heymsfield, S.B.; Ross, R. Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability. *J. Am. Geriatr. Soc.* **2002**, *50*, 889–896. [[CrossRef](#)]
143. Wen, X.; Wang, M.; Jiang, C.-M.; Zhang, Y.-M. Are current definitions of sarcopenia applicable for older Chinese adults? *J. Nutr. Health Aging* **2011**, *15*, 847–851. [[CrossRef](#)]
144. Zoico, E.; Di Francesco, V.; Guralnik, J.M.; Mazzali, G.; Bortolani, A.; Guariento, S.; Sergi, G.; Bosello, O.; Zamboni, M. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. *Int. J. Obes. Relat. Metab. Disor.* **2004**, *28*, 234–241. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).